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                                                                          Abstract 
 
Recent work has indicated that respiratory Complex I may be the sole source of reactive 
oxygen species (ROS) during ischemic-reperfusion (IR) injury. However, evidence 
collected by several groups, including ours, has demonstrated that Complex III and Krebs 
cycle enzymes are also high capacity sites for ROS production. Here, the ROS producing 
capacity of Complex I was examined in hearts subjected to IR injury. Using mice deficient 
in Complex I (NDUFS4
+/-
), the respiratory chain was found to be the main source of ROS 
in cardiac and liver mitochondria. However, Complex III was found to be the major source, 
producing ~50% of the total ROS, while Complex I accounted for ~30%. Partial deletion 
of Complex I sensitized hearts towards reperfusion injury, increasing infarct size, which 
correlated with higher ROS production. Collectively, these results refute the claim that 
Complex I is the sole source of ROS following IR injury. 
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1. Introduction 
1.1 Nutrient Metabolism 
Nutrient metabolism is defined as the breakdown or biosynthesis of carbon containing 
molecules through various pathways to maintain cell function(s). These molecules are either 
degraded or produced by catabolic and anabolic pathways, respectively (1). Catabolism refers to 
the breakdown of organic materials for the production of ATP, the universal energy currency 
required to fulfill most, if not all, cellular and physiological functions (2). Anabolic reactions, on 
the other hand, divert organic materials from central catabolic cascades towards “cell building” 
pathways (e.g. lipogenesis or the production of nucleotides). These pathways are also vital for 
the provision of NADPH, a reducing equivalent that serves as the “bed rock” of antioxidant 
defenses and production of the building blocks of the mammalian cell (2). Carbohydrates, amino 
acids, and fatty acids derived from dietary sources are the main drivers of nutrient metabolism. 
These molecules are metabolized by distinct metabolic pathways that yield common 
intermediates that converge on the Krebs cycle which is the most central metabolic pathway. 
Upon entry into the Krebs cycle, carbon units are systematically oxidized, and the electrons 
released from this metabolic cascade are used to drive ATP biosynthesis via a process called 
oxidative phosphorylation. Krebs cycle intermediates can also be diverted to support other 
metabolic pathways including the biosynthesis of amino acids, heme groups, small molecule 
hormones, lipids, and nucleotides (2).  
1.1.1 Glycolysis 
After food is ingested, carbohydrates are broken down into their constituent 
monosaccharides (e.g. glucose, fructose, and galactose), absorbed by the gut, and then released 
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into circulation for distribution around the body (2). These monosaccharides are then taken up by 
cells and used to generate 2 ATP and 2 pyruvate by glycolysis (Figure 1.1). The first five steps of 
glycolysis are defined as the “preparatory phase”, which includes the breakdown of glucose into 
two three carbon groups, a process that requires ATP. Glucose is first activated through its 
phosphorylation on the carbon-6 position by hexokinase (EC 2.7.1.1) in the presence of ATP and 
Mg
2+
, forming glucose-6-phosphate (1,2). In the liver, this reaction is catalyzed by glucokinase 
(EC 2.7.1.2), a hexokinase isoenzyme that displays unique catalytic properties that prevent its 
allosteric deactivation by glucose-6-phosphate, a critical characteristic that is vital for glucose 
clearance after a meal (3,2). In the next step, phosphohexose isomerase (EC 2.7.1.11) converts 
glucose-6-phosphate to fructose-6-phosphate (4,2). Phosphofructokinase-1 (PFK-1) (EC 
2.7.1.11) phosphorylates fructose-6-phosphate on the C-1 position producing fructose-1,6-
bisphosphate (5,2). Aldolase (EC 4.1.2.13) then cleaves fructose-1,6-bisphosphate into 
dihydroxyacetone phosphate and glyceraldehyde-3-phosphate (2). Triose phosphate isomerase 
(EC 5.3.1.1) is required to convert dihydroxyacetone phosphate into glyceraldehyde-3-phosphate 
(2). 
The other half of the glycolysis pathway is defined as the “payoff phase” since the triose 
phosphates yielded in the preparatory phase are used to make ATP by substrate level 
phosphorylation. First, glyceraldehyde-3-phosphate is oxidized and phosphorylated by 
glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) in the presence of NAD
+
 and 
inorganic phosphate forming NADH and 1,3-bisphosphoglycerate (6). The phosphate on the one 
position is used to form ATP, a reaction catalyzed by phosphoglycerate kinase (7). 
Phosphoglyceromutase (EC 5.3.1.1) then transfers the phosphate from the carbon-3 position to 
the second carbon and enolase forms the high energy intermediate phosphoenolpyruvate (2). The 
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last step also involves the substrate level phosphorylation of ADP, by pyruvate kinase (EC 
2.7.1.40), producing pyruvate in the process. When mammalian cells are deprived of oxygen, 
pyruvate is reduced by lactate dehydrogenase (EC 1.1.1.27) in the presence of NADH to 
replenish NAD
+
 for glycolysis (8). When oxygen is available, however, pyruvate is oxidized 
further by the Krebs cycle in mitochondria (9).  
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Figure 1.1-The glycolytic pathway 
This pathway demonstrates the breakdown of glucose into pyruvate. 
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1.1.2 Beta-Oxidation  
Fatty acids constitute an important source of energy, particularly during starvation. In 
addition, organs like the heart rely heavily on fatty acid oxidation to meet ATP demands. It has 
been estimated that heart tissue can turn over ~30 kg of ATP a day and ~70-90% of this energy is 
supplied by the beta-oxidation of fatty acids in mitochondria (10). Beta-oxidation takes place in 
the matrix of mitochondria and thus fatty acid metabolism relies on the import of fatty acids into 
the matrix environment. To do so, the CoASH group in fatty acyl-CoA is first replaced with 
carnitine in the intermembrane space environment by carnitine palmitoyl transferase-1 (CPT-1) 
(EC 2.3.1.21), which facilitates the entry of fatty acids into the mitochondrial matrix (11). Once 
the fatty acids enter the matrix, CPT-2 (EC 2.3.1.21), a CPT-1 isozyme, exchanges carnitine for 
CoASH and β-oxidation is initiated. First, acyl-CoA dehydrogenase (EC 1.3.8.1) oxidizes acyl-
CoA forming an enoyl-CoA, which contains an unsaturated region between the alpha and beta 
carbon. Hydrides yielded from the oxidation are used to reduce FAD to FADH2 and then these 
electrons are transferred to the ubiquinone (UQ) pool in the mitochondrial inner membrane (12). 
The unsaturated region is then hydrated and -hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35) 
oxidizes β-hydroxyacyl-CoA producing NADH and β-ketoacyl-CoA. In the last step, the β-
ketoacyl-CoA is metabolized by thiolase (EC 2.3.1.16) to facilitate the formation of acetyl-CoA 
and a fatty acid chain shortened by two carbons (2). Oxidation of fatty acids continues until it is 
completely broken down to its constituent acetyl-CoA molecules (13). Acetyl-CoA produced 
from β-oxidation then enters the Krebs cycle where it is broken down further. 
1.1.3 Citric acid cycle 
A complete overview of the Krebs cycle is given in Figure 1.2. Pyruvate yielded from 
glycolysis or amino acid degradation must first be imported to the mitochondrial matrix by the 
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symporter pyruvate translocase (also referred to as pyruvate carrier or monocarboxylate 
transporter), and then converted to acetyl-CoA by the pyruvate dehydrogenase (PDH) (EC 
1.2.4.1) complex. Thus, PDH is the important entry point for carbohydrates. PDH is composed of 
three subunits: 1) the E1 subunit (pyruvate decarboxylase) (EC 6.4.1.1), which decarboxylates 
pyruvate in the presence of thiamine pyrophosphate (TPP), 2) the E2 subunit (dihydrolipoyl 
transacetylase), which transfers the acetyl group on TPP to a lipoamide residue. The E2 subunit 
then catalyzes the transfer of the acetyl group to CoASH forming acetyl-CoA and reduced 
dihydrolipoamide, and 3) The E3 subunit (dihydrolipoyl dehydrogenase) oxidizes 
dihydrolipoamide reducing FAD. The hydrides on FADH2 are then transferred to NAD
+
 
producing NADH (15). Figure 1.3 gives a detailed description of the catalytic mechanism for 
PDH.  
Since PDH is the entry point for carbohydrates into the Krebs cycle, it is also an 
important site for the regulation of metabolism. High ATP/ADP and NADH/NAD
+ 
ratios, acetyl-
CoA and long chain fatty acids allosterically inhibit PDH (15). Pyruvate dehydrogenase kinase 
and pyruvate dehydrogenase phosphorylase also play a key role in controlling PDH activity 
through phosphorylation of the E1 subunit (15). PDH is also regulated by redox signals through 
reversible oxidation of its E2 subunit by protein S-glutathionylation (10). Pyruvate is also 
metabolized by pyruvate carboxylase (EC6.4.1.1), which is required to prime the Krebs cycle 
through the formation of oxaloacetate. Once formed, oxaloacetate condenses with acetyl-CoA 
and forms citrate through a Claisen condensation reaction, a reaction catalyzed by citrate 
synthase. Citrate is then isomerized through a cis-aconitate intermediate by aconitase forming 
isocitrate. Next, the first irreversible step of the Krebs cycle is catalyzed by isocitrate 
dehydrogenase (EC 1.1.1.42) which couples the decarboxylation of isocitrate to the reduction of 
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NAD
+
. Notably, mitochondria also contain an isozyme for isocitrate dehydrogenase that couples 
isocitrate oxidation to the production of NADPH, a key moiety required for antioxidant defense 
and lipogenesis in the matrix. The 2-oxoglutarate generated by isocitrate dehydrogenase is 
oxidized by 2-oxoglutarate dehydrogenase (OGDH) (EC 1.2.4.2). This is the second irreversible 
step of the Krebs cycle since 2-oxoglutarate oxidation is coupled to the evolution of CO2 and 
formation of NADH. Amino acids can enter the Krebs cycle at the level of 2-oxoglutarate in the 
Krebs cycle via glutamate metabolism (16). The oxidation of 2-oxoglutarate by OGDH yields 
succinyl-CoA. OGDH and PDH are homologous in structure and thus have a similar mechanism 
for forming NADH. The E1 subunit for OGDH also relies on TPP for the decarboxylation of 2-
oxoglutarate and is thus called 2-oxoglutarate decarboxylase (17).  The E2 subunit is referred to 
as dihydrolipoyl-succinyltransferase (EC 2.3.1.61) which produces succinyl-CoA (18). The 
dihydrolipoyl dehydrogenase (EC 1.8.1.4) subunit for OGDH is interchangeable with the E3 
subunit of PDH (18). Like PDH, OGDH also plays an important role in the regulation of the 
Krebs cycle. High ratios of ATP/ADP, NADH/NAD
+
 inhibit the complex. Moreover, high 
amounts of succinyl-CoA are also responsible for an allosteric inhibition (2). OGDH is also 
tightly regulated by reversible oxidation of its vicinal thiols on dihydrolipoamide and is also 
controlled through the S-glutathionylation of the E1 and E2 subunits (10).  
After its formation, succinyl-CoA is converted to succinate by succinyl-CoA synthetase 
(EC 6.2.1.4), which couples the hydrolysis of the thioester bond between CoASH and succinate 
to the production of ATP (adenosine 5’- triphosphate) or GTP (guanosine 5’-triphosphate) (19). 
In the next step, succinate dehydrogenase (EC 1.3.5.1), which is a membrane bound enzyme, 
facilitates the production of fumarate and FADH2 from succinate. This enzyme is also referred to 
as Complex II and is considered to be part of the electron transport chain since it couples the 
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oxidation of succinate directly to the reduction of UQ (ubiquinone) to UQH2 (ubiquinol) in the 
electron transport chain (ETC). Fumarase (EC 4.2.1.2) then hydrates fumarate producing malate 
which is oxidized by malate dehydrogenase (EC 1.1.1.41) forming NADH and oxaloacetate. For 
every molecule of acetyl-CoA which enters the Krebs cycle, 2 CO2, 3 NADH, 1 FADH2 and 1 
GTP/ATP molecule are produced (20). The CO2 formed by carbon oxidation is either converted 
to carbonic acid by carbonic anhydrase (EC 4.2.1.1) or exhaled from the body. NADH and 
FADH2 produced by the Krebs cycle are used to drive oxidative phosphorylation by the electron 
transport chain. 
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Figure 1.2-The Citric acid cycle  
This diagram gives the detailed description of the various steps involved in the Krebs cycle. 
ACN (Aconitase), IDH (Isocitrate dehydrogenase), GLS (Glutamine synthase), AT 
(Aminotransferase), GDH (Glutamate dehydrogenase), OGDH (2-oxoglutarate dehydrogenase), 
SCS (Succinyl-CoA synthetase), SDH (Succinate dehydrogenase), FUM (Fumarase), MDH 
(Malate dehydrogenase), CS (Citrate synthase). 
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Figure 1.3-Pyruvate dehydrogenase complex 
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1.1.4  Electron transport chain 
Mitochondria are double membraned organelles that fulfill many functions in mammalian 
cells. These organelles play integral roles in calcium buffering and the induction of apoptosis. 
However, these other roles are often overshadowed by its most important function, the provision 
of cellular ATP. Mitochondrial ATP production is carried out by the ETC, sometimes just 
referred to as the respiratory chain, which couples the movement of electrons to the 
phosphorylation of ADP. Electrons from NADH and FADH2 travel through respiratory 
Complexes I-IV to the terminal electron acceptor O2 at the end of the chain. Energy released 
from the favorable “downhill” transfer of these electrons is used by Complex V to make ATP. 
Once formed, ATP is exported into the cytosol to perform useful work. Mitochondria make up 
~30-40% of the volume of a cardiomyocyte and are thus vital for heart physiology and function. 
For example, ATP produced by mitochondria in cardiomyocytes is utilized to maintain the ion 
gradients and drive the motor proteins required for the pumping of oxygenated blood around the 
body (10). Mitochondria supply ~90% of the ATP for heart function which is derived from many 
carbon sources including ketone bodies, lactate, and glucose. However, the main source of ATP 
in cardiomyocytes is fatty acids, which account for ~70-90% of the ATP formed by heart 
mitochondria. Figure 1.4 below gives the description of the ETC chain. 
The first step of oxidative phosphorylation involves the oxidation of NADH and 
succinate by Complex I. Complex I (NADH: ubiquinone oxidoreductase) consists of 45 subunits, 
7 iron-sulfur (Fe-S) clusters and a flavin mononucleotide (FMN), making it the largest complex 
in the ETC (19). It is worthy to point out that only 12-13 of these subunits, some of which are 
encoded by the mitochondrial genome, are required to drive the catalytic activity of Complex I. 
The other 33 subunits, like NDUFS4, are required for the assembly of Complex I, maintenance 
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of its native conformation, and the formation of supercomplexes. When fully assembled, 
Complex I takes on an “L” shaped conformation comprised of three separate modules. The N-
module makes contact with the matrix environment and couples the oxidation of NADH to the 
reduction of FMN, which then passes electrons through the 7 Fe-S clusters. The Q-module serves 
as the interface between the N and P-modules and contains the UQ binding pocket. The 
reduction of UQ and release of UQH2 is coupled to the pumping of protons in to the 
intermembrane space by the P-module. Note that the P-module forms the hydrophobic part of 
Complex I and is thus responsible for the insertion of the respiratory complex into the 
mitochondrial inner membrane (20). Complex I is an important site for regulation of respiration. 
It can adopt activated (A-form) and deactivated (D-form) conformations in response to changes 
in the availability of NADH (21). Complex I activity is also modulated by a variety of redox 
signals like S-glutathionylation and the assembly/disassembly of supercomplexes (10). 
The second complex of the ETC is Complex II (succinate-coenzyme Q reductase or 
succinate dehydrogenase). This ~120 kDa complex is made up of four subunits designated 
subunits A – D (22, 23). Subunits A and B are in contact with the matrix. Meanwhile, subunit C, 
as well as D, are required for partial insertion in the mitochondrial inner membrane. Note that 
unlike Complexes I, III, and IV, succinate dehydrogenase does not span the inner membrane and 
is thus not involved proton export. In addition, in contrast to the other complexes, the Gibbs free 
energy change for succinate oxidation and UQ reduction is ~0 kJ/mol. Therefore, not enough 
energy is released from Complex II to warrant a conformational change for proton export. The 
binding sites for succinate and bound FAD are enclosed in subunit A. Succinate from the Krebs 
cycle binds to Complex II where it gets oxidized to fumarate releasing 2 electrons. These 
electrons are then transferred to the FAD unit of Complex II, generating FADH2 (24). Complex 
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II also contains 3 Fe-S clusters which are required to transfer electrons from FADH2 to the UQ 
binding site. During high rates of succinate oxidation, electrons are cycled between a Fe-S 
cluster and a heme group of subunit C to prevent overflow and electron leaks (24).  
Complex III (ubiquinol: cytochrome c oxidoreductase) is comprised of 11 subunits and 
couples the oxidation of UQH2 to the reduction of cytochrome c. (25). The Rieske iron-sulfur 
protein (RISP) and cytochrome c1 are the two main subunits involved in the passage of electrons 
to cytochrome c.  Notably, cytochrome c is hydrophilic and found in the interspace where it 
binds to the outer leaflet of the inner membrane through electrostatic interactions with Complex 
III. Like Complexes I and II, the Fe-S clusters in RISP and cytochrome c1 can only accept one 
electron at a time. Therefore, UQH2 is initially incompletely oxidized to a semi-ubiquinone 
radical (UQH
●-
). This can be dangerous since UQH
●-
 can form reactive oxygen species (ROS) 
and loss of these electrons will also diminish ATP output making oxidative phosphorylation 
inefficient. To deal with this issue, Complex III recycles the second lone electron in UQH
●- 
through the Q-cycle. This requires two heme groups (cytochrome bL and bH) (26). First, UQH2 
and UQ bind to the QO site and the Qi site of Complex III respectively. The QO site is positioned 
near the outer leaflet of the inner membrane close to RISP, whereas the Qi is positioned closer to 
the matrix. Oxidation of UQH2 in the QO site results in the transfer of one electron to RISP while 
the transfer of the second electron to Qi is facilitated by cytochrome bL and bH. For complete 
reduction of ubisemiquinone in Qi, a second UQH2 is oxidized in the QO site and the second 
electron is passed to the Qi binding site. Unlike Complex I and IV, Complex III is not a pump but 
rather uses a Mitchellian redox loop to move protons into the intermembrane space. In addition, 
the Gibbs free energy change for electron flow is not as high as Complex I and IV. Therefore, 
only 2 protons are shuttled out of the matrix instead of four.  
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Complex IV is composed of 14 subunits, but only three subunits are thought to 
participate in the transfer of electrons to molecular oxygen (27). These three subunits are: 
subunit I, subunit II, subunit III (1). Subunit I includes a copper ion (Cu3) and two heme groups 
(a and a3) which combine to form the a3: Cu3 binuclear center (28). When two cytochrome c 
molecules are reduced, they bind to subunit II. These electrons are then transferred to heme a via 
the CuA center. While heme transports these electrons to the a3: Cu3 center of Complex IV, O2 
binds to the heme groups and is completely reduced to water. In the course of this entire process 
four protons are released to the intermembrane space (29). The transport of two electrons and the 
release of four protons from this complex leads to the formation of two H2O molecules at the 
end. 
The “downhill” movement of electrons from NADH or succinate to O2 at the end of the 
chain is thermodynamically favourable and is responsible for the production of the 
electrochemical gradient of protons across the inner membrane. This proton gradient is produced 
by Complex I, III and IV and the electrochemical difference in protons across the mitochondrial 
inner membrane is called the membrane potential or “proton motive force” (PMF) (30). The 
proton motive force is composed of electrical (ΔΨM) and chemical (ΔpH) components with the 
former making up ~90% of the overall “force” of  
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Figure 1.4-The electron transport chain 
Transport of electrons from NADH and succinate through the complexes to O2 at the end of the 
chain. The protons released into the intermembrane space during the process leads to ATP 
production. 
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the gradient. Oxidation of NADH and succinate results in the pumping of 10 and 6 protons into 
the intermembrane space, respectively.  
The overall strength of the proton gradient depends on the rate of proton extrusion and 
return to the matrix. This invariably depends on the rate of ADP phosphorylation by Complex V 
and the rate of electron flow to Complex IV. Other factors can be used to enhance proton return 
to the matrix. The leak of protons by chemical uncouplers or uncoupling proteins, for example, 
can dissipate the proton gradient. Protons are also used for the transport of solutes or import of 
proteins into the matrix. Protons can also be return through complexes I and III during reverse 
electron flow (31). However, a hyperpolarized mitochondrial inner membrane is required to 
drive reverse flow. Overall, the potential across the mitochondrial inner membrane is ~150-180 
mV. When normalized to the diameter of mitochondrial inner membrane, the total force 
experienced by a mitochondrion is ~300,000 V cm
-1
 (assuming the inner membrane is 5-7 nm 
thick) (31).  
Complex V (also referred to as ATP synthase) uses the Gibbs free energy stored in the 
proton gradient to generate chemical energy in the form of ATP. There are two main functional 
domains in ATP synthase: 1) FO domain: found in the inner mitochondrial membrane and is 
comprised of the channel that facilitates the downhill transport of the protons and 2) F1 domain: 
this domain includes the catalytic active sites and is located peripherally to the inner membrane 
of the matrix (32). The F1 domain is made up of five subunits: , , , , and  (32). The  shaft 
which is coupled to one of the  subunits, is thereby encircled by three  and  subunits. There 
are three  subunits which have the similar composition but differ in conformation and this 
difference is likely caused due to their association with the  subunit. These  subunits can be 
found in three separate conformations which are directly associated with the binding of ADP and 
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Pi and the subsequent formation of a γ-phosphodiester bond: 1) -ADP- which binds to the ADP, 
2) -ATP-which contains the newly formed ATP and 3) -empty-which does not include any 
substrates (33). The transport of the protons from the Fo domain triggers the 120 rotation of the 
 subunit which is critical for 1) the binding of the next  subunit, 2) causing a change in their 
conformation. This rotation of the F1 is referred to as rotational catalysis. Initially a  subunit 
occurs in the -ADP conformation state which changes to -ATP form, when ADP and Pi bind 
to the -ADP site (33). This -ATP form is beneficial to confine the substrates together and 
hence facilitate phosphorylation. After ATP is generated, the conformation changes to the -
empty state and ATP is liberated. (33). If one -subunit occurs in the -ADP form, the other two 
are found to be in their -ATP and the -empty state. The three  subunits rotate through all 
three conformations, catalyzing the formation of three ATP molecules for one full rotational 
round of the  subunits. These ATP molecules thus generated are used in various cellular 
processes. 
1.2 Regulation of reactive oxygen species levels  
Reactive oxygen species (ROS) are produced via the incomplete reduction of molecular 
oxygen. Due to its unique chemical features, O2 can only accept one electron at a time. 
Therefore, during the reduction of O2 to H2O, several oxygen-containing free radical 
intermediates are formed, namely, superoxide (O2
-
), hydrogen peroxide (H2O2), and hydroxyl 
radical (OH
•
) (34). Although there are a number of ROS sources in physiology, mitochondria are 
the main site for production in most mammalian cells. This is due to the high concentration of 
flavin groups and UQ, which can donate one electron to O2 generating ROS (34). The proximal 
ROS formed by mitochondria was once considered to be O2
- 
(35). However, it is now accepted 
that mitochondria directly form a mixture of O2
-
 or H2O2, which is dependent on flavin radical 
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chemistry (35).  It has been estimated that 0.02-2% of the total amount of oxygen consumed by 
mitochondria forms ROS (36, 37). ROS have a bi-functional relationship with mammalian cells 
where they are required to control various cell programs through signaling at low doses, whereas 
in excess amounts they can overwhelm antioxidant systems and cause oxidative distress. Use of 
ROS in signaling has recently been defined as oxidative eustress whereas oxidative distress 
occurs when levels are too high, overwhelming antioxidant defenses (42). Oxidative distress is 
typically associated with ROS accumulation and oxidative damage, which correlates strongly 
with the development of cardiovascular, inflammatory, and degenerative diseases (38). In cardiac 
tissue, the over production of ROS is associated with development of a myocardial infarction, 
ischemia-reperfusion injury, left ventricular hypertrophy, reperfusion arrhythmias, heart failure 
and fibrosis (38). Superoxide can induce oxidative distress through the rapid disassembly of Fe-S 
clusters necessary for mitochondrial metabolism (39). Hydrogen peroxide, on the other hand, can 
induce oxidative damage by irreversibly oxidizing cysteine thiols in low molecular weight 
molecules and proteins (40). Several essential redox-active metals like Fe and Cu can react with 
ROS to give rise to OH
 
via Fenton and
 
Haber-Weiss reactions. Several nucleotides, lipids, and 
amino acids are targets for oxidation by OH
 
leading to DNA damage, protein and lipid 
oxidation, and inducing cell death (41). 
 By contrast, low grade ROS production is required for cell signaling, also called oxidative 
eustress. For instance, low grade ROS production in cardiac tissue has been shown to enhance 
contractile efficiency, bolster cell stress responses, and protect from reperfusion damage (41). 
Hydrogen peroxide is the main ROS secondary signaling molecule and regulates protein function 
through the site specific and reversible oxidation of “cysteine switches”. Notably, these switches 
serve as sensors for overall changes in the cell redox environment and are required for the 
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induction of stress signaling pathways like Nrf2 activation, T-cell activation (43), adipocyte 
differentiation (44) and steroidogenesis (45). Hydrogen peroxide is an important secondary 
messenger and like any other signaling molecule its overall abundance is regulated through its 
production and degradation. The mitochondria utilize H2O2 routinely in cell communication and 
thus it uses several systems to control its rate of production and overall concentration. 
Antioxidant systems are required for the degradation of H2O2 signals. Mitochondria are enriched 
with H2O2 removing enzymes (45). Production on the other hand, is controlled by regulating 
electron entry and exit from sites of formation. Electron availability for production is controlled 
through proton leaks, supercomplex assemblies, and redox signals.  
1.2.1 Antioxidant defence systems 
Mitochondrial and cellular O2
●-
 levels are generally maintained in the picomolar range by 
the rapid action of superoxide dismutase (SOD), which converts two O2
●-
 into one H2O2 and one 
H2O at a rate of 2.3 x 10
9
 M
-1 
s
-1 
(48).  In mitochondria, this reaction is catalyzed by manganese-
dependent SOD (SOD2) in the matrix and the Cu/Zn-dependent isozyme (SOD1) in the 
intermembrane space (48). Once formed H2O2 can be degraded by several different enzyme 
systems. The main H2O2 quenching systems in mitochondria are glutathione (GSH) and the 
thioredoxin (TRX) systems (47). However, catalase can also remove H2O2 in the matrix of 
mitochondria in liver and cardiac cells (46). 
Mitochondria do not synthesize GSH and are thus reliant on its uptake from the cytosol 
(50). The concentration of GSH in the matrix is ~5 mM (49). Removal of H2O2 by the 
glutathione system is catalyzed by glutathione peroxidase-1 (GPX1) in the matrix of 
mitochondria. GPX1 removes H2O2 by forming a disulfide bridge between two GSH molecules, 
forming oxidized glutathione (GSSG), also called glutathione disulfide (51, 52, 53). The 
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concentration of GSSG in the matrix of mitochondria is ~0.01-1 mM due to the action of 
glutathione reductase (GR), which rapidly reduces GSSG in the presence of NADPH to reform 
GSH. Mitochondria also contain a second glutathione peroxidase isoform called GPX4 and it 
couples the degradation of lipid hydroperoxides, an intermediate in lipid peroxidation, to the 
oxidation of GSH. It is important to note that the GSH/GSSG ratio does display rapid changes in 
oxidation which is utilized to convey redox signals (53). Oxidation of glutathione pools is 
accompanied by the protein S-glutathionylation of protein cysteine thiols and serves as an 
important regulatory device for mitochondrial function (discussed below).  
The thioredoxin (TRX) system is the second major H2O2 degradation pathway in 
mitochondria and relies on the catalytic activity of peroxiredoxin (PRX) (54). Mitochondria 
contain two PRX isozymes, PRX3 and PRX5. PRX3 displays a catalytic preference for the 
elimination of H2O2 whereas PRX5 reacts mostly with lipid hydroperoxides. All PRX enzymes 
are homodimers that contain two catalytic cysteine thiols on each monomer called the 
peroxidatic cysteine (CysP) and resolving cysteine (CysR) (54). Each monomer is also organized 
in a head-to-tail orientation. First, CysP reacts with H2O2 forming a sulfenic acid residue (SOH). 
Next, the SOH is resolved by CysR on the neighboring monomer forming a disulfide bridge. 
Disulfide bridge formation between the monomers deactivates the catalytic activity of PRX3 and 
PRX5. Reactivation requires reduction by TRX2 (thioredoxin-2) through a disulfide bond 
exchange reaction. Oxidized TRX2 is then reactivated by thioredoxin reductase-2 (TR2) and 
NADPH.  
1.2.2 Proton leak 
The role of proton leaks in quenching O2
-
/H2O2 production is well documented but also 
happens to be one of the most contentious issues in the field of mitochondrial bioenergetics.  
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Proton leak is a physiological process where protons are returned to the matrix of the 
mitochondria by-passing ATP synthesis (55). Physiological leaks were first found to contribute 
to non-shivering thermogenesis in brown fat, where the Gibbs free energy released from the leak 
of protons back into the matrix generates heat to maintain body temperature (55, 56). However, 
proton leaks in other tissues, like the heart and muscle, have been found to also regulate ROS 
production. There are two types of leak mechanisms that allow proton reuptake by mitochondria; 
basal leak and inducible leak. Basal leak involves the unregulated import of protons into the 
matrix by adenine nucleotide translocase (ANT) (56). Inducible leaks on the other hand represent 
a regulated form of mitochondrial proton return by uncoupling proteins (UCP) 1-3 (56, 57). ROS 
production is highly sensitive to the changes in proton leak. Indeed, small increases in the proton 
motive force correlates with a non-Ohmic increase in mitochondrial ROS release (63). This is 
associated with the over-reduction of the respiratory chain, increasing the number of electrons 
available for ROS production. Therefore, proton return can reduce protonic back pressure on the 
respiratory chain, augmenting electron flow and lowering ROS production. 
Overproduction of ROS by the mitochondria and oxidative distress is associated with the 
loss of UCP2 or UCP3 (58). The end products of lipid peroxidation, 4-hydroxynonenal (4-HNE) 
and O2
●-
 have been found to induce proton leak by UCPs (58). Activation of leaks by O2
●-
 or 4-
HNE was suggested to serve as a negative feedback loop for the regulation of ROS release by 
augmenting leaks (59). UCP1-3 have been found to control ROS release in response to an 
increase in protonic back pressure in various tissues including heart, skeletal muscle, pancreas, 
brain, and brown fat (60,61). Overexpression of both UCP2 and UCP3 leads to decreased ROS 
production while their inhibition has the opposite effect (62).  
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1.2.3 Supercomplexes 
The criteria that dictate electron entry and exit from sites of ROS release include 
substrate supply and type, access to O2, and the redox state and concentration of the electron 
donating site. Thus, factors that can augment electron flow to O2 at the end of the chain can 
diminish ROS release by limiting the over reduction of electron donating centers. The individual 
complexes of the respiratory chain have been found to interact with one another and form what 
are called “respirasomes”. These supercomplexes, which are comprised of Complexes I, III, and 
IV, UQ, and cytochrome c, and sometimes Complex V, have been found to be vital for assuring 
efficient respiration and electron flow. Assembly of these complexes is also important for 
controlling ROS release. Indeed, by assembling into a supercomplex, efficient electron flow 
from Complex I and IV can be assured, limiting the number of electrons that can contribute to 
ROS production. This is highlighted by studies that have found that supercomplex disassembly, 
or defects in respirasome formation, correlates strongly with heart disease and neurological 
disorders (64). The increase in ROS release due to disassembly is thought to occur through the 
accumulation of electrons in Complex I, but recent work has also found that this also occurs at 
Complex III (64). 
 Protein S-glutathionylation is defined as the addition and removal of a glutathione moiety 
to a protein cysteine thiol residue (65). These reactions are sensitive to changes in the 
surrounding redox environment through fluctuations in the availability of GSH and GSSG, 
which is affected by the levels of H2O2 and NADPH (65). Unlike other redox modifications, S-
glutathionylation reactions are rapid, reversible, and highly specific, since they are mediated by 
specialized enzymes that sense changes in GSH and GSSG (66). Mitochondria are a hot spot for 
S-glutathionylation, containing protein targets involved in energy metabolism, ROS release, 
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mitochondrial shape, and solute import (Table 1.1). In mitochondria, S-glutathionylation 
reactions are facilitated by the thiol oxidoreductase glutaredoxin-2 (GRX2). GRX2 serves as a 
GSH /GSSG sensor that S-glutathionylates or deglutathionylates target proteins in response to 
fluctuations in the matrix redox environment. An increase in GSSG results in GRX2-driven S-
glutathionylation of protein targets in mitochondria, whereas restoration of the reductive 
potential of the glutathione pool has the opposite effect. Recent work by our group, and others, 
have demonstrated that this reaction mechanism is integral for the negative regulation of ROS 
release in liver tissue (63,65,66). S-glutathionylation of PDH and OGDH was found to limit ROS 
release from either enzyme complex which is reversed by GRX2 (66). However, S-
glutathionylation has the opposite effect in cardiac mitochondria. Over S-glutathionylation of 
these complexes for instance has been found to augment ROS production and increase sensitivity 
to heart disease (66). Loss of GRX2 is associated with left ventricular hypertrophy and recent 
work has established that variations in GRX2 nucleotide sequence correlates strongly with 
development of heart disease in humans (66). Therefore, controlled S-glutathionyation through 
GRX2 is vital for regulating ROS release from mitochondria. 
Even though S-glutathionylation could be mediated enzymatically, oxidizing conditions 
could lead to the spontaneous S-glutathionylation of proteins (67). Oxidative distress could result 
in higher concentrations of GSSG inducing the non-enzymatic S-glutathionylation of a cysteine 
through a simple disulfide exchange reaction. These reactions are often associated with oxidative 
damage and the disabling of protein function due to nonspecific protein S-glutathionylation. 
However, in some instances, spontaneous protein S-glutathionylation has been shown to protect 
enzymes from oxidative damage. For instance, Complex I and OGDH have been found to be 
protected from irreversible oxidative damage by H2O2 through the S-glutathionylation of reactive 
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cysteines required for their enzymatic activity (67). By blocking the thiol residue, H2O2 (when at 
high cellular concentrations) cannot irreversibly form sulfinic and sulfonic acids (67). One more 
mechanism of spontaneous S-glutathionylation occurs when the protein cysteine thiol residues 
reacts with GSH to give rise to a thiol radical glutathionyl intermediate, which then gets oxidized 
to produce protein glutathione mixed disulfide (PSSG) (68). Several enzymes like succinate 
dehydrogenase exhibited persisted S-glutathionylation under physiological conditions (68). The 
susceptible nature of proteins and the formation of GSSG possessing microenvironments by the 
proteins can lead to changes in the criteria which promote S-glutathionylation (68). In addition to 
oxidative stress S-glutathionylation also plays a major role in energy metabolism. Several 
processes like mitochondrial shape, protein import, proton leakage and apoptosis have also been 
found to make use of S-glutathionylation (68). 
1.3 NDUFS4 subunit 
 
Complex I is the first component of ETC and is made up of 45 subunits (154,105). One 
of these subunits includes NDUFS4 (NADH dehydrogenase [ubiquinone] iron-sulfur protein 4 or 
NADH-ubiquinone oxidoreductase) which is encoded by the Ndufs4 gene (154,105). NDUFS4 
protein occurs in the matrix of the inner mitochondrial membrane of the mitochondria (154,105). 
Thus, it helps in removal and electrons from NADH and facilitates the transport of these 
electrons to ubiquinone (154,105). Mutation in this gene leads to several genotypical and 
phenotypical disorders (105). In our experiments we completely knocked out the NDUFS4 
protein which is a subunit of Complex I to form NDUFS4
-/- 
mice. These mice developed severe 
fatal encephalomyopathy and heart disease by 5-6 weeks of age, which is associated with 
deficiencies in linear growth (105). Also, these mice homozygous for the Ndufs4 gene develop 
alopecia, blindness, and display stunted growth and lethargy (105). Moreover, disorders like 
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Parkinson disease, neuropathy, liver disease are also caused in humans due mutation in Ndufs4 
gene (154,105).  
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Table 1.1-The targets of S-glutathionylation  
The mitochondrial proteins that are found to be S-glutathionylated since 2013 are listed in this 
table  
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1.4 Cardiac anatomy and physiology 
1.4.1 Pumping of blood from the heart 
The human heart is a muscular organ found in the thoracic cavity and is protected by a 
fibrous membrane called the pericardium. The outer layer of the pericardium is attached to the 
diaphragm whereas the inner layer is known as the epicardium which covers the heart. The 
cavity between the epicardium and endocardium is known as the pericardial cavity. This cavity 
contains the pericardium fluid which protects the heart from friction and shock (69). The heart is 
a four-chambered organ. The upper two chambers are known as the atrium and the lower two 
chambers are known as the ventricles. There occurs a tricuspid valve between the right atrium 
and the right ventricle and a bicuspid valve between the left atrium and left ventricle. The vena 
cava collects the deoxygenated blood from the body and empties it to right atrium which is then 
pumped into the left ventricle via the tricuspid valve. The function of the valve is to prevent the 
backflow of the blood. Then from the right ventricle the blood is taken to the lungs for 
oxygenation by the pulmonary artery. The superior and inferior pulmonary veins collect the 
oxygenated blood from the lungs and transports it to the left atrium which is pumped to the left 
ventricle via the bicuspid valve (69). From the ventricle, the oxygenated blood is then supplied to 
the entire body via the aorta. 
Little resistance is provided by the lungs to the blood flow which keeps the right atrium 
and right ventricle at low pressure. (69).The auricles contract to pump blood into the ventricles. 
Before the auricles contract, around 75% of the ventricle gets filled with blood. Subsequently, 
the AV node sends impulses to the auricles to contract and pump blood into the ventricles (71). 
The final 25% of the ventricle is filled due to this contraction of the atrium. Deregulation of the 
AV node causes the impulses to be delayed and thus delays the contraction of the auricles. The 
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valves open to facilitate the flow of blood to the ventricles from the auricles and close to prevent 
the flow of blood back to the auricles (70). These valves make a sound on opening and closing 
and analysis of these sounds can be utilized to determine the integrity of the valves. There are 
two sounds which are made during each heartbeat. The first sound is low pitched and is known 
as “lubb”, while the other high pitched sound is known as “dub”. These sounds resemble the 
pulse of the heart. Lubb is internally divided into two parts depending on the frequency: 1) the 
sound made due to the closure of the tricuspid valve and 2) the sound made due to the closure of 
the bicuspid valve/mitral valve (72). As the cardiac cycle begins from the right part of the heart, 
the sound from the tricuspid valve is heard before the bicuspid valve. Dubb is also divided into 2 
parts: 1) the sound due to the closure of the aortic valve (A) and 2) the sound due to the closure 
of the semilunar valves (P). P is louder than A. If the valves do not close properly there would 
either be a leakage or the narrowing of the valves which could disturb the sound of the pumping 
(73). Systolic murmur and diastolic murmur occurs when there are any problems in the shutting 
of the bicuspid/tricuspid valves and aorta/semilunar valves and blood leaks back to the right and 
the left auricle respectively.  
1.4.2 Pacemaker regions of the heart  
The normal pumping of the blood from the heart is maintained by pacemaker regions. 
The action potential which is mediated by several ion channels in the heart are responsible for 
the electric activity in the myocardium (74). 
Action potential basically depicts the sequential activation and inactivation of Na
+
 and
 
K
+
 
ion channels which causes depolarization and repolarization. The sinoatrial (SA) node is the 
initiator of all the electrical signals in the myocardium (75, 76, 77). From the SA node the signals 
are then transmitted to the atrioventricular (AV) node which via purkinje fibres spread the 
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electric signals to the entire heart. Due to the excitation of the myocardial cell, an action potential 
is generated followed by relaxation and a refractory period until the generation of the next 
impulse (78, 79, 80, 81). There are different waveforms generated during an action potential. The 
waveforms of action potentials are different in different types of tissue (82, 83, 84, 85, 86). In the 
artrial and ventricular cardiomyocytes the upstroke of an action potential is quite rapid due to the 
opening of Na channels and is thus termed as phase 0. This phase 0 is followed by phase 1 which 
is the repolarization stage where the Na channels are inactivate and the K current is activated. 
This repolarization phase occurs for a brief time period in the purkinje fibres and thus effects the 
duration of phase 2. During phase 2 the voltage gated Ca
+2
 channels are activated and thus there 
is an influx of calcium ions via the L-type calcium channels (87). The activation of Ca
+2
 
channels triggers the excitation mediated contraction of the myocardium. These channels also 
help in generating action potentials in the SA nodes and AV node cells. Other types of Ca
+2 
channel known as T type calcium channels also occur which plays a role in automaticity and 
have similar properties to the L type Ca
+2
 channels. During this phase, the force which is 
required for the efflux of K
+
is also high (88). As soon as the Ca channels are inactivated, the 
outward K
+
 currents dominate, causing the membrane to repolarize and resulting in the 
restoration of the resting potential. There are several voltage gated (Kv) and non-voltage gated 
(Kir) K
+
 currents (89). There are two types of currents produced by them 1) inward 2) outward. 
The outward current is then divided into IKr [IK (rapid)], IKs [IK (slow)], and IKur [IK 
(ultrarapid)]. Depending upon the type of tissue and any disease condition, the amount of 
expression and the property of each of these channels varies (250). Several pore forming 
subunits and channel accessory units have been found to encode Nav, Cav, Kv, and Kir channels. 
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Any mutations in these encoding genes were found to be responsible for cardiac arrhythmia (89, 
90). 
1.5 Ischemia-reperfusion injury to the myocardium  
Ischemia is defined as a lack of oxygen supply to the tissue but can also be associated 
with diminished delivery of metabolic substrates to an organ compromising ATP production (91, 
92, 93, 94). Depending upon the severity of an ischemic injury, the resulting damage could be 
reversed by the restoration of blood flow to the tissue which is called reperfusion. Reperfusion 
not only restores the oxygen and the nutrient levels of the tissue, but also replenishes ATP. 
However, Hearse et al. in 1973 found that reperfusion after ischemia can also paradoxically 
induce tissue injury. This re-oxygenation-dependent tissue damage is referred to as “reperfusion 
injury” (96). 
ROS were originally suggested to play a part in reperfusion injury in the 1980s (95, 96). 
It was found later that this was associated with a burst in ROS production following 
reintroduction of O2 overwhelming antioxidant defenses and inducing oxidative distress, cell 
death, and tissue damage (96). Reperfusion injury has been studied in the heart, brain, skeletal 
muscle, liver, and kidney (140). Reperfusion injury induces arrhythmia and myocardial 
infarction, which is associated with necroptosis, apoptosis, and impaired microvascular function 
(96). Several in vitro models have been designed to study the response of heart cell populations 
towards simulated ischemia and reperfusion injury (97). These studies demonstrated that 
reperfusion injury is associated with the over production of ROS by mitochondria. Moreover, 
mice pre-treated with mitochondria-targeted antioxidants, electron transport chain blockers that 
limit ROS production, or exposed to ischemia pre-conditioning are protected from IR (ischemic 
reperfusion) induced injury (97). Other factors that can curtail the reperfusion-mediated 
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induction of oxidative distress and cell death include cyclosporin A, an inhibitor of 
mitochondrial permeability transition pore opening (MPTP) (138). Notably, MPTP opening is 
also associated with the over production of mitochondrial ROS. 
The importance of mitochondrial ROS in the induction of reperfusion injury was further 
demonstrated using experimental models where antioxidant defenses were manipulated through 
the overexpression or deletion of genes encoding enzymes that eliminate ROS (98). Studies 
carried out with cell populations challenged with conditions that mimic ischemia-reperfusion 
also showed enhanced production of ROS (98). The above lines of evidences showed that ROS 
played a vital role in the injury caused during reperfusion (97, 98). Previous studies utilized SOD 
(superoxide dismutase), which is a O2
- 
scavenger, in the presence/absence of catalase to 
demonstrate the protective effects towards I/R (ischemic reperfusion) injury (147,148). Several 
mice models were used where the expression of ROS scavenging enzymes was modulated also 
demonstrated an association of ROS and I/R induced injury (141,142,143). Experiments carried 
out with cultured cardiomyocytes treated with H2O2 also induced effects that were similar to I/R-
induced tissue injury (99). Malondialdehyde, conjugated dienes, and hydroxynonenol which are 
obtained due to lipid peroxidation are often regarded as the markers for ROS generation in 
various models (144,145). Oxidative stress and redox imbalance which is mostly created during 
I/R conditions, is marked by the generation of oxidized glutathione (GSSG) or by the oxidation 
of sulfhydryl groups. The ROS production was also quantified using several oxidant-sensitive 
fluorochromes (146). Nowadays proteomic and genomic mapping of the cells which are 
challenged to I/R injury is done where the responses to oxidative stress is noted (139). Thus, to 
conclude, the relationship between ROS and I/R induced injury is well studied (100,101). 
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1.5.1 ROS production during ischemic-reperfusion injury of the heart 
During ischemia, the lack of O2 significantly diminishes the combustion of fuels that 
drive ATP production by oxidative phosphorylation, including the beta-oxidation of fatty acids. 
In an effort to meet energy demands, cardiomyocytes increase glucose uptake and enhance the 
glycolytic production of ATP. Since pyruvate cannot be metabolized by mitochondria, it is 
diverted towards the production of lactate, acidifying the cellular environment. In addition, 
glycolysis produces considerably less ATP than oxidative phosphorylation and, therefore, a 
significant energy debt develops in the myocardium. This also stimulates adenylate kinase, 
producing ATP by transferring a beta-phosphate from ADP to another ADP molecule. This also 
generates AMP, prompting its breakdown by the purine degradation pathway (102). The caveat 
to this mechanism is that it results in the accumulation of hypoxanthine which, following 
reintroduction of O2, is metabolized by xanthine oxidase inducing a burst in ROS production.  
During ischemia, there is also a slowing of electron transfer through the respiratory chain which 
results in the over reduction of redox centers in Complexes I-IV (130). There is also a slowing of 
the Krebs cycle and the accumulation of several intermediates, including succinate which is 
considered a biomarker for I/R injury (102). Reintroduction of O2 induces a burst of ROS release 
by mitochondria which is associated with MPTP opening and the induction of apoptosis and 
necrosis (Figure 1.5) (102).  Recent work by Chouchani et al suggests that MPTP opening and 
the induction of tissue damage is induced by O2
●-
 release from Complex I and induction of 
MPTP within 15 seconds of reperfusion (102). The authors demonstrated that succinate 
accumulation during ischemia due to purine nucleotide metabolism and the slowing of the Krebs 
cycle is responsible for igniting the massive increase in ROS release by Complex I. The 
succinate-induced increase in Complex I-mediated ROS release is due to the reverse flow of 
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electrons from Complex II. Reverse electron transfer (RET) is a natural phenomenon where 
electrons can flow backwards in the respiratory chain from Complex III or Complex II to 
Complex I under the right bioenergetic conditions (102). One of the main factors required is a 
high PMF to promote RET through Complex I and the reduction of NADH. Another important 
factor that influences RET is the ratio of NADH/NAD 
+ 
(102). For RET to occur, NAD
+
 needs to 
be available to accept electrons during reverse flow. In the model proposed by Chouchani et al, 
after ischemia, cardiac mitochondria retain a high PMF and sufficient amounts of NAD
+
 to 
promote rapid electron flow from succinate to Complex I inducing a massive burst in ROS 
production and MPTP (Figure 1.5) (102). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
 
 
 
                 Figure 1.5-The mechanism of IR injury 
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1..5.2 Problems with the Chouchani model for IR injury to the myocardium 
 In Chouchani et al, it was proposed that Complex I was the only source of the ROS 
during IR injury (102). However, there are several pitfalls associated with this model. The first is 
that Complex I adopts a deactivated “D” state during ischemia. The A to D transition occludes 
the UQ binding site completely suppressing Complex I activity (103). Transition back to an “A” 
(active) state following re-introduction of oxygen and metabolites takes a few minutes (103,115). 
Therefore, Complex I cannot engage in RET for the first few minutes after reperfusion. The 
nicotinamide pool in the matrix of mitochondria is also highly reduced during ischemia which 
would curtail RET (103,115). Therefore, reverse electron flow through Complex I to FMN, the 
site for O2
●-
, may not be possible. The second issue with this model is that it is well known that 
MPTP opening occurs within seconds following reperfusion and is induced by overloading the 
mitochondrial matrix with calcium (115). The overproduction of ROS was documented to 
happen well after MPTP opening (115). In addition, MPTP favors forward electron transfer due 
to the depolarization of the mitochondrial inner membrane and ADP debt. These conditions 
would not favor reverse electron flow from succinate to Complex I. The final major issue 
associated with this model is that it completely ignores the other sites for ROS production in 
mitochondria. Recent work has shown that mitochondria can contain up to 12 potential ROS 
forming sites (103). These ROS forming sites can be subcategorized based on the electron donor 
utilized in the genesis of O2
●-
/H2O2; the NADH/NAD+ isopotential group and the UQH2/UQ 
isopotential group as shown in Figure 1.6 (103). ROS forming sites associated with the former 
group including NADH producing and oxidizing enzymes that contain a flavin residue, namely, 
OGDH, PDH, branched chain amino acid dehydrogenase (BCKDH), 2-oxoadipate 
dehydrogenase (OADH), and Complex I. The latter group is comprised of enzymes that donate 
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or accept electrons directly from the UQ pool in the respiratory chain and includes Complexes II 
and III and various enzymes that adbsorb to the outer leaflet of the inner membrane. Several 
studies have established that the main sites for ROS release in muscle and liver mitochondria are 
Complex III and OGDH, and to a lesser extent PDH and Complex II (104, 110, 111).This 
appears to also be the case for cardiac mitochondria. Two recent studies by our group found that 
Complex I and III both serve as major ROS sources in cardiac mitochondria (110,111). 
However, OGDH and PDH can also produce a significant amount as well (104). These 
observations are in line with several studies that have demonstrated Complex III is a major 
source for ROS during IR injury (132,103). Inhibitors for Complex III ROS release, like 
stigmatellin and myxothiazol, have been found to curtail IR injury (135). The last issue 
associated with the Chouchani model is timing for the opening of the MPTP following 
reperfusion. This occurs within seconds following reperfusion and results in a complete collapse 
of the mitochondrial membrane potential (115,116). In an effort to restore the PMF, forward 
electron flow from Complex I and II is augmented resulting in a massive spike in O2 
consumption (115,116). Therefore, it would seem more likely that other mitochondrial ROS 
producers are involved in IR injury and that the bioenergetics of the cardiac mitochondria do not 
favor reverse electron flow to Complex I from succinate (115,116).  
 
 
 
 
 
 
37 
 
 
         
 
Figure 1.6-Sources of ROS in the ETC 
The known sources of ROS production are described in the above diagram. The two major 
isopotential sites involved in ROS production are 1) NADH/NAD
+ 
isopotential site 2) QH2/Q 
isopotential sites. The NADH/NAD
+ 
isopotential site includes OGDH (2-oxoglutarate 
dehydrogenase), PDH (pyruvate dehydrogenase), OADH (2-oxoadipate dehydrogenase), and 
BCKDH (branched chain keto acid dehydrogenase). QH2/Q isopotential sites are SQR 
(sulfide:quinone oxidoreductase), DHODH (dihydroorotate dehydrogenase), PRODH (proline 
dehydrogenase), G3PDH (sn-glycerol-3-phophate dehydrogenase), ETFQO (electron transfer 
flavoprotein-ubiquinone oxidoreductase), Complex I, Complex II and Complex III. 
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1.6 Research objectives 
 
  The major objectives of my thesis are as follows: 
1. To examine the impact of Complex I deficiency on mitochondrial O2
●-
/ H2O2 production 
and identify high capacity sites in cardiac and liver mitochondria.  
2. To determine the impact of partial Complex I deficiency on myocardial reperfusion 
damage. 
3.  To ascertain if NADH can drive ROS production by RET in Complex I knockouts. 
 
1.7 Hypothesis 
The major hypothesis of my research project are as follows: 
1. Complex I is not the sole source of ROS in mitochondria and Complex I deficiency will 
not alter O
2
●-
/H
2
O
2
 production by cardiac and liver mitochondria. 
2. Partial deletion of Complex I will sensitize the myocardium towards reperfusion injury. 
3. NADH will drive ROS production in Complex I knockouts. 
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2. Materials and Methods 
2.1 Breeding and maintaining mice 
Male and female mice heterozygous for the Ndufs4 gene (Ndufs4
+/-
) were purchased from 
Jackson Laboratory (Bar Harbor, ME, USA). Briefly, mice heterozygous for Ndufs4 were 
generated using a 129/sv mouse strain using standard gene eliminating techniques (Ndufs4 
flanked by loxp to remove exon 2 of the gene) (105). 129/sv mice were then backcrossed by 
several generations with C57Bl/6N mice to facilitate proper phenotypic analyses and increase 
fertility. Mice were housed in ventilated cages and fed a standard chow diet (44.2% 
carbohydrate, 6.2% fat, 18.6% crude protein; diet T.2018, Harlan, Indianapolis, IN) ad libitum 
and given free access to water. Mouse were housed at room temperature (~23°C, 12 hour (h) 
dark/12h light cycle, lights on at 0700h). Age-matched male and female mice heterozygous for 
Ndufs4 were paired for breeding. Once pregnancy was confirmed, male mice were removed and 
new litters were weaned at three weeks of age. Female mice were either culled or kept for future 
breeding. Immediately after weaning, mice were ear notched for genotyping. Ear notches were 
stored at -20 °C for genotyping. At 10-11 weeks of age, WT or NDUFS4
+/-
 mice were either 
euthanized for the isolation of cardiac and liver mitochondria or hearts extracted for ischemic-
reperfusion injury. The capacity of NADH to drive ROS release by reverse electron transfer to 
OGDH or PDH was examined using mice partially knocked-out for Ndufs4 (NDUFS4
+/-
). 
NDUFS4
-/- 
mice develop encephalomyopathy, lose motor function, develop blindness, and 
display retarded growth by ~5-6 weeks of age (105). Therefore, these experiments were 
conducted on mice no more than 5 weeks of age. WT and NDUFS4
+/- 
mice were weighed 
weekly until euthanasia to compare rate of growth. Breeding of these mice was performed by 
myself and Danielle Gardiner (Research technician in Dr. Mailloux lab) also helped me during 
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this procedure. All experiments were approved by Memorial University’s Animal Care and Use 
committee and conducted according to institutional and Federal animal care guidelines.  
2.2 Mouse genotyping  
2.2.1 DNA isolation 
DNA was extracted from ear notch samples using a REDExtract-N-Amp Tissue PCR Kit 
(Sigma-Aldrich) according to the manufacturer’s instructions. One hundred microliters of 
Extraction Solution and 25 L Tissue Prep Solution were pipetted into a 1.5 mL microcentrifuge 
tube containing an ear notch. Samples were incubated at 55°C for 10 mins followed by an 
incubation of 95°C for 3 mins. After this, 100 L of Neutralization Solution was added to each 
tube and then samples were vortexed. Samples were used for polymerase chain reaction (PCR) 
or stored at -20 ºC for later use. 
2.2.2 Polymerase Chain Reaction (PCR)  
Primers for Ndufs4 were obtained from Integrated DNA Technologies. Table 2.1 shows 
the detailed primer sequences. The PCR tube contained the following: 0.5 M Ndufs4 wild type 
forward primer (1 L), 0.5 M Ndufs4 reverse primer (1 L), 0.5 M Ndufs4 mutant forward (1 
L), DNA solution (4 L), nuclease-free water (3 L) and REDExtract-N-Amp Tissue PCR Kit 
Reaction Mixture (10 L). The final volume in the tube was 20 L. Eppendorf Mastercycler pro 
PCR System was used to amplify the DNA. Table 2.2 shows the PCR Protocol for amplification 
of the Ndufs4 gene. 
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Table 2.1-DNA Sequence of primers used for Ndufs4 genotyping 
 
Primer Sequence 
 Ndufs4 Wild type Forward 5’-AGT CAG CAA CAT TTT GGC AGT -3’ 
Ndufs4 Reverse primer 5’-GAG CTT GCC TAG GAG GAG GT -3’ 
Ndufs4 Mutant Forward 
 
5’-AGG GGA CTG GAC TAA CAG CA -3’ 
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Table 2.2-Polymerase Chain Reaction (PCR) protocol for Ndufs4 genotyping 
 
Step Temperature (ºC) Time 
1 94 2 min 
2 
10 cycles 
94 20 sec 
65 15 sec 
68 10 sec 
3   
4 
28 cycles 
94 15 sec 
60 15 sec 
72 10 sec 
5   
6 72 2 min 
Hold 10  
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2.2.3 Polyacrylamide gel electrophoresis 
PCR samples were electrophoresed in a 1.5% agarose gel which was made by dissolving 
0.75 g of agarose powder (Fisher Scientific) in 0.5X Tris-Borate-EDTA (TBE, 10X solution 
diluted to 0.5X in analytical water) under constant heat. SYBR Safe DNA Gel Stain (Fisher 
Scientific) was added to the molten agarose at a 1/10,000 dilution. The gel was allowed to 
solidify in the gel molding of a Fisher Biotech Horizontal Electrophoresis Systems gel box. 
Trackit 100 bp DNA Ladder (Fisher Scientific) was used as a reference to estimate the DNA 
fragment size. The samples were loaded into the gel and it was electrophoresed for 40 mins at 
90V. Ndusf4 gene fragments were visualized using an Alpha Innotech ChemiImager Ready 
System. A single nucleotide sequence produced by the WT mice was 200 base pairs (bp) in 
length while the NDUFS4
-/-
 mice produced a fragment 400 bp in size. The NDUFS4
 +/-
 mice 
contained both nucleotide fragments (200 bp and 400 bp). It may seem unusual that the PCR 
product corresponding to the Ndufs4 gene lacking the second exon is larger than the WT gene. 
According to Jackson laboratories, deletion of exon 2 moves the forward primer for Ndufs4 
closer to the common primer, giving a band that is ~400 bp in size. Therefore, the presence of 
exon 2 generates a PCR product of a smaller size.   
2.3 Isolating the mitochondria  
Liver and cardiac mitochondria were isolated using protocols established by our group 
(110,111). Prior to each isolation, 1 liter of MESH buffer (23.95 g sucrose; 70 mM, 40.1 g 
mannitol; 220 mM, 0.38 g EGTA; 1 mM, 5.2 g HEPES; 20 mM, pH 7.4) was made and stored at 
4 °C. On the day of experimentation, mitochondrial isolation buffer was made by adding   0.5% 
(w/v) fatty acid-free bovine serum albumin (BSA; Sigma-Aldrich) to MESH buffer (abbreviated 
MESH-B). All mitochondrial isolation steps were performed on ice or at 4 °C.  Mice were 
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deeply anesthetized with isoflurane and then euthanized by cervical islocation. The cardiac and 
liver tissues of these mice were collected and stored in MESH-B. The cardiac and liver tissues 
were dabbed dry and weighed. Femur length was also recorded and used to normalize heart 
weight. Tissues were first cut into small pieces with scissors and rinsed with MESH-B to remove 
excess blood. Tissue pieces were then minced with a razor on a Teflon watch glass and then 
placed in a homogenizer with 15 mL MESH-B. For cardiac tissue, MESH-B was also 
supplemented with 1 unit of subtilisin A (Sigma-Aldrich). Subtilisin A is a protease that was 
added to release mitochondria from myofibers. The amount added was determined according to 
equation 2.1.  
 
Equation 2.1-Volume of Subtilisin A to be added 
                       
                 
                    
 
 
For liver mitochondria, homogenates were centrifuged at 800 x g for 9 mins at 4 °C to 
remove nuclei and undisrupted tissue. The supernatant was then collected and centrifuged at 
10,000 x g for 9 mins. The supernatant was decanted and the resulting mitochondrial pellet was 
resuspended in 20 mL of fresh MESH-B and centrifuged again at 10,000 x g. The washing step 
was carried out to remove any contaminating organelles and fat. The solution was decanted and 
the resulting mitochondrial pellet was resuspended in 500 L MESH buffer and stored on ice.  
Cardiac mitochondria were isolated by centrifuging the homogenate at 10,000 x g for 9 
mins. The supernatant was decanted and the pellet was resuspended in 15 mL MESH-B to 
remove any residual protease. The homogenate was then centrifuged at 800 x g for 9 mins to 
remove nuclei and myofibers. After this, the supernatant was centrifuged for 10 mins at 10,000 x 
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g. The resulting cardiac mitochondrial pellet was resuspended in 100 l MESH and stored on ice. 
Protein equivalents to mitochondrial content were estimated using the Bradford assay. 
2.3.1 Bradford assay for protein estimation 
Protein equivalents to mitochondria were determined using the Bradford assay. Protein 
concentration was estimated using a standard curve generated with BSA (Sigma-Aldrich) with a 
concentration range from 0 to 1.875 µg/ml (Figure 2.1). For sample quantification, 1 µL of the 
mitochondrial suspension was added to 999 µL of analytical water and then vortex thoroughly in 
a 1.5 ml microcentrifuge tube. After this, 50 µL of diluted sample was added to 200 µL Bradford 
reagent (Sigma-Aldrich) and the volume was adjusted to 1 ml with analytical water. Samples 
were then mixed and 200 µL of sample was pipetted into the wells 96 well plate (Greiner Bio-
One) in duplicate. The equation y = mx+b was used to calculate the final concentration of protein 
equivalents to mitochondria. Samples were then stored on ice for assays. Any additional 
mitochondria remaining at the end of experiment was stored at -80 °C for immunoblot. 
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Figure 2.1-Bradford assay standard curve for determination of protein concentration 
 
The absorbance was measured with increasing concentrations of BSA mixed with Bradford 
reagent. Hence, the unknown concentration of the protein can be determined 
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2.4 Amplex Ultra Red (AUR) assay 
Amplex Ultra Red (AUR) assay was used to selectively measure the rate of O2
●-
/H2O2 
production. Although AUR is selective for H2O2, it cannot discriminate between H2O2 formed 
directly by sites of ROS production or by the dismutation of O2
●-
 by superoxide dismutase 
(SOD). Indeed, sites of ROS release in mitochondria have been documented to release a mixture 
of O2
●-
 and H2O2, a characteristic associated with flavin-based prosthetic groups (6). Therefore, 
in this thesis, AUR measurements are referred to as the measurement of O2
●-
/H2O to account for 
1) H2O2 produced directly by sites of production and, 2) H2O2 produced due to dismutation of 
O2
-
. In this assay exogenous SOD was added to ensure the full conversion of O2
- 
to H2O2.  
Before experiments, liver samples were diluted to 3 mg/ml and the cardiac samples to 1 mg/mL 
in MESH-B (110). These samples were then stored on ice. Twenty microliters of sample were 
added to the wells of a 96 well plate containing MESH and in the absence or presence of 
different inhibitors. Experiments with ROS production inhibitors required incubating samples at 
25 °C for 10 min in the presence of the inhibitor (110). AUR reagents were then added and 
reactions initiated by the addition of substrate. The final volume for each reaction was 200 µL 
and the final concentration of liver and cardiac mitochondria in each well was 0.3 mg/mL and 
0.1 mg/ml, respectively. Changes in fluorescence associated with the conversion of non-
fluorescent AUR to fluorescent resorufin were tracked using a SpectraMax M5 plate reader to 
measure the fluorescence every 30 seconds for a duration of 5 mins at 565/600 nm excitation and 
emission wavelengths. A standard curve generated by different concentrations of H2O2 (30 % 
stock solution at 12.8 M, Sigma-Aldrich) ranging from 20-400 nM was used for calculating the 
amount of ROS production (Figure 2.2). 
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Figure 2.2-AUR Assay standard curve for determination of O2
-
/H2O2 concentration 
 
The fluorescence was measured with increasing concentrations of hydrogen peroxide. Hence, the 
unknown concentration of the O2
-
/H2O2 can be determined. 
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2.4.1 Measuring rate of O2
-
/H2O2 production during PDH and 2-OGDH oxidation 
          There can be up to 12 sites of ROS production in mitochondria which includes enzymes 
that feed electrons directly to the ubiquinone pool, Complex I, Complex II, Complex III and 
Krebs cycle enzymes (103). In order to determine which enzymes serve as high capacity sites for 
production and whether or not a deficiency in the NDUFS4 protein influences individual rates of 
production, mitochondria were treated with different inhibitor and substrate combinations. To 
examine ROS release associated with the Krebs cycle and electron transport chain, pyruvate and 
2-oxoglutarate with malate were utilized as substrates. Malate was included to complete the 
Krebs cycle ensuring the full oxidation of substrates. OGDH and PDH inhibitors as well as 
Complex II and III inhibitors were also used to pinpoint which sites formed the most ROS.  
Pyruvate (50 µM) or 2-oxoglutarate (50 µM) with malate (50 µM), were used to 
determine the O2
-
/H2O2 in the liver and cardiac mitochondria. Our group showed previously that 
these substrate concentrations (which represent physiological concentrations) induce a 
measureable rate of O2
-
/H2O2 production (110). In the individual wells of a 96 well plate, 
mitochondria were added to MESH buffer containing 10 mM α-keto-β-methyl-n-valeric acid 
(KMV; OGDH inhibitor) (Sigma-Aldrich), 250 M 6,8-bis(benzylsulfanyl) oclanoic acid (CPI-
613; OGDH and PDH inhibitor) (Sigma-Aldrich), 40 M Atpenin A5 (Santa Cruz; Complex II 
inhibitor), or 4 M myxothiazol (Sigma-Aldrich; Complex III inhibitor) and then incubated at 25 
C   for 10 min (110). Myxothiazol acts as a selective inhibitor of Complex III. It prevents 
semiquinone formation by binding to the ubiquinone binding site close to the outer leaflet (Qo) 
of the mitochondrial inner membrane (Figure 2.3). α-Keto-β-methyl-n-valeric acid (KMV) is a 
structural analog of 2-oxoglutarate and is thus a site-specific inhibitor for OGDH. Atpenin A5 
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inhibits Complex II by blocking its ubiquinone binding pocket. Also, CPI-613 effectively 
inhibits OGDH and PDH by competitively binding the lipoic acid in the E2 subunit. After 
mitochondria were incubated in the presence or absence of the different inhibitors, 25 U/mL 
SOD (Sigma-Aldrich), 3 U/mL HRP (Sigma-Aldrich), 10 M AUR (Invitrogen), and 50 M 
malate was added in each well. Reactions were initiated by adding 50 M pyruvate or 50 M 2-
oxoglutarate. Changes in fluorescence were tracked as described above.  
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Figure 2.3-Sites of action for the different inhibitors used in the AUR assays 
 Rotenone and atpenin A5 inhibit Complex I and Complex II respectively by blocking 
ubiquinone binding sites, IQ and IIQ, respectively. Myxothiazol blocks the QO site of Complex III 
preventing semiquinone production and ROS release. KMV selectively blocks ROS release from 
OGDH and CPI-613, a structural analog for lipoic acid, inhibits both PDH and OGDH. 
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2.4.2 Measuring rate of O2
-
/H2O2 production during succinate oxidation 
Succinate is oxidized by Complex II of the respiratory chain donating electrons directly 
to the ubiquinone pool (Figure 2.3). In these reactions, pyruvate was also excluded to prevent the 
full oxidation of succinate following the production of fumarate. Excluding pyruvate prevents 
the completion of the Krebs cycle abolishing ROS release from PDH and OGDH. Therefore, 
these experimental conditions allow for the exclusive measurement of O2
●-
/H2O2 release from 
the electron transport chain. First, 20 l of heart mitochondria was added to individual wells 
containing MESH with or without different inhibitors and then incubated for 20 min at 25 °C. 
We used 4 M rotenone (Sigma-Aldrich), 40 M atpenin A5 (Santa Cruz) or 4 M myxothiazol 
(Sigma-Aldrich), Complex I, II, and III inhibitors, respectively, to pinpoint the site of ROS 
release during succinate oxidation (Figure 2.3). Sites of action for myxothiazol and atpenin A5 
were described in the previous section. Rotenone, a Complex I inhibitor that competitively 
blocks its ubiquinone binding pocket, was used to ascertain how much ROS was formed during 
reverse electron flow from succinate (Figure 2.3). After the incubation, 25 U/mL SOD (Sigma-
Aldrich), 3 U/mL HRP (Sigma-Aldrich), and 10 M AUR (Invitrogen). Reactions were initiated 
by the addition of 50 M succinate. Using a SpectraMax M5 plate reader the rate of ROS 
production was monitored for every 30 seconds for a duration of 5 mins at 565/600 nm. 
2.4.3 Measuring rate of O2
-
/H2O2 production during RET from NADH. 
The mitochondrial inner membrane is a selectively permeable barrier that does not allow 
the free diffusion of solutes between the matrix and intermembrane space. Thus, mitochondria 
were permeabilized to promote the uptake of exogenously added NADH by the mitochondrial 
matrix and ascertain if it can contribute to ROS release by reverse electron flow. Note that these 
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experiments were carried out with mitochondria enriched from NDUFS4
-/- 
mice. This ensured 
that NADH could not be oxidized by Complex I and thus any ROS production could be 
attributed to PDH or OGDH (or another 2-oxoacid dehydrogenase). Mitochondria were 
permeabilized using a protocol previously established by our group (112). Liver and heart 
mitochondria were diluted to 3 mg/mL and 1 mg/mL, respectively, in MESH containing Triton 
X-100 (0.05% v/v). Samples were then vortexed and incubated on ice for 20 minutes. After 
permeabilization, 20 µL aliquots of mitochondrial suspension were added to individual wells of a 
96-well black plate containing MESH. Twenty-five U/mL SOD (Sigma-Aldrich), 3 U/mL HRP 
(Sigma-Aldrich), 10 M AUR (Invitrogen) were then added to each well and then reactions were 
initiated by the addition of NADH (0.1-10 µM final concentration in each well). Using a 
SpectraMax M5 plate reader the rate of ROS production was monitored for every 30 seconds for 
a duration of 5 mins at 565/600 nm. 
2.4.4 Immunoblot 
Liver and cardiac mitochondria stored at -80 °C were thawed, vortexed vigorously, and 
then placed on ice. Samples were diluted to 1 mg/ml in analytical water containing Laemmli 
buffer (2X stock diluted to 1X in water, Bio-Rad) and heated for 10 minutes at 100C. Proteins 
were separated in a 12% acrylamide gel to ensure proper immunodetection of the NDUFS4 
protein (~20 kDa in size), glutathione peroxidase-1 (GPX1), or thioredoxin-2 (TRX2). Succinate 
dehydrogenase subunit A (~70 KDa) served as the loading control for all experiments. The 
resolving gel solution was made by adding 6 mL of 40% acrylamide solution (36.7% w/v 
acrylamide /3.3 % w/v bis-acrylamide, Biorad) to a 50 mL conical tube containing 5 mL of 4X 
Trizma /SDS solution (1.5 M Trizma base +0.4% (w/v) SDS in 100 mL of analytical water, pH 
8.8 with HCl) and 10 mL of analytical water. The gel solution was mixed and polymerization 
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was initiated by adding 75 µL of TEMED (N, N, N', N'-tetramethylethane-1, 2-diamine, Biorad) 
and 150 µL 1% (w/v) APS (ammonium persulfate solution, Biorad). Table 2.3 shows a detailed 
recipe of the gel. The gel solution was then quickly poured into the gel cast (filling the cast by 
~3/4) and then the gel was overlaid with 100% isopropyl alcohol and allowed to polymerize. 
After resolving gel polymerization, the isopropyl alcohol was removed and the gel was overlaid 
with a stacking gel. The stacking gel was prepared in a 15 mL conical tube and contained 1 ml 
40% acrylamide (to make a total volume of 4% (v/v)), 2.5 ml 4X Trizma/SDS stacking gel 
solution (0.5 M Trizma Base + 0.4% (w/v) SDS in 100 mL, pH 6.8). The volume was adjusted to 
10 ml with analytical water. Fifty microliters of TEMED and 75 µL of APS was added to initiate 
gel polymerization. After the stacking gel was added to the gel cast, a 15 well comb (1 mm) was 
immediately inserted into the stacking gel. After polymerization, the comb was removed and the 
wells dabbed dry.  
Prior to experiments, a 10X electrophoresis buffer was made and stored at room 
temperature [1920 mM glycine, 1% (v/v) SDS (sodium dodecyl sulfate) and 25 mM Trizma 
base]. The electrophoresis buffer was diluted to 1X just before the experiments by adding 100 ml 
10X electrophoresis buffer to 900 ml analytical water. Samples were loaded into the individual 
wells of the gel. PageRuler Plus prestained protein ladder (Fermentas, 15 µL) was also loaded 
into the gel to track protein migration and confirm the successful transfer of proteins to the 
nitrocellulose membrane and the molecular mass of proteins of interest. Samples were initially 
electrophoresed at 80 V. Once the running front entered the resolving gel and the prestained 
ladder started to separate, the voltage was increased to 240 V. As soon as the running front 
reached the bottom of the gel, electrophoresis was stopped. Gels were then removed and 
equilibrated for 15 min at room temperature under constant agitation in 1X transfer buffer (100 
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mL of 10X transfer buffer in 800 mL of analytical water and 100 mL methanol), which was 
made by diluting 100 mL of 10X transfer (500 mM Trizma, 380 mM glycine, 10% w/v SDS) in 
900 mL analytical water. One times transfer buffer was also used to equilibrate nitrocellulose 
membranes (Bio-Rad) and extra thick blotting paper (Bio-Rad). A Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad) containing 1X transfer buffer was used to transfer 
proteins from the resolving gel to the surface of a nitrocellulose membrane. Protein transfer was 
carried out at 120 V for 1 hr at room temperature. Successful transfer of proteins was confirmed 
by staining nitrocellulose membranes with Ponceau S (Sigma-Aldrich). Membranes were then 
rinsed with Trizma-buffered saline (TBS; 1 mM Trizma base, 68 mM NaCl) containing 0.1% 
(v/v) Tween-20 (Bio-Rad) (TBS-T). Nonspecific binding sites on membranes were then blocked 
with TBS-T containing 5% w/v non-fat skim milk (Lab Scientific) for 1 hour at room 
temperature under constant agitation. Membranes were then washed thrice with TBS-T for 5 
minutes. Membranes were then probed overnight at 4 °C with constant agitation with anti-SDHA 
(Santa-cruz, catalogue #sc-377302) and anti-Ndufs4 (Santa-Cruz, catalogue #sc100567) or anti-
SDHA (Santa-cruz, catalogue #sc-377302) and anti-GPX1 (Santa-cruz, catalogue #sc-133160) or 
anti-SDHA (Santa-cruz, catalogue #sc-377302) and anti-TRX2 (Santa-cruz, catalogue #sc-
137028) antibodies diluted in TBS-T + 5% (w/v) BSA + 2% (w/v) NaN3 (Sigma-Aldrich). The 
primary and secondary antibodies were diluted as per table 2.4. Membranes were washed thrice 
with TBS-T for 5 mins and then probed with secondary antibodies conjugated to horseradish 
peroxidase (HRP). Depending on the primary antibody, the secondary antibody (goat antibody 
conjugated to HRP; anti-mouse or anti-rabbit) was added in the blocking solution containing the 
membrane. The above solution was agitated for 70 mins at room temperature. WestPico Super 
Signal Chemiluminescent substrate was added as well. The ImageQuant LAS 4000 system was 
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utilized for viewing the immunoreactive bands. These immunoblots were performed in 
duplicates.  
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Table 2.3-Detailed recipe of the immunoblot gel  
 
 40% 
Acrylamide/Bis 
Solution (mL) 
4X 
Tris/SDS 
8.8 
Buffer 
(mL) 
4X 
Tris/SDS 
6.8 
Buffer 
(mL) 
Analytical 
water 
(mL) 
TEMED 
(L) 
APS 
(L) 
12% 
Resolving 
Gel 
6 5 0 9 150 75 
4% 
Stacking 
Gel 
1 0 2.5 6.5 75 50 
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Table 2.4-Dilution factor for the antibodies  
 
Antibodies Antibody 
(L) 
TBS-T 
(mL) 
NaN3 
(L) 
Final 
concentration 
(L) 
 Loading 
control 
Anti-SDH A 
(primary Ab) 
3.33 10 0.02 1/3000 
 
Goat anti-mouse 
(secondary  
Ab-HRP conjugate) 
 
3.33 10 0.02 1/3000 
 
Ndufs4 
antibody 
 
Anti-Ndufs4 
(primary Ab) 
10 10 0.02 1/1000 
Goat anti-mouse 
(secondary  
Ab-HRP conjugate) 
 
3.33 10 0.02 1/3000 
 
GPX1 
antibody 
 
Anti-GPX1 
(primary Ab) 
5 10 0.02 1/2000 
Goat anti-mouse 
(secondary  
Ab-HRP conjugate) 
 
3.33 10 0.02 1/3000 
 
TRX2 
antibody 
 
Anti-TRX2 
(primary Ab) 
5 10 0.02 1/2000 
Goat anti-mouse 
(secondary  
Ab-HRP conjugate) 
 
3.33 10 0.02 1/3000 
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2.5 Isolated heart perfusions  
This experiment was conducted as described previously (112). Briefly, the Krebs-Henseleit (K-
H) buffer including 7 mmol/l glucose, 0.4 mmol/l oleate, 1% BSA, and 10 εU/ml insulin was 
prepared and oxygenated (95% O2; 5% CO2 gas). A peristaltic pump connected with silicon 
tubing was used to pump the KH buffer into the Langendorff perfusion system at a flow rate of 4 
ml/min (Figure 2.4). The flow rate at 4 ml/min maintains a normal mouse coronary pressure in 
vivo.  
The WT and NDUFS4
+/- 
mice (n=10) aged 10-11 weeks were initially heparinized (100 U 
i.p) in order to prevent blood coagulation prior to anesthesia They were then anesthetized with 
pentobarbital sodium (60 mg/kg i.p). Hearts were excised and cannulated with aorta.  A balloon 
was inserted into the left ventricle to measure the hemodynamic function of the heart. . During 
the baseline perfusion, the balloon was inflated to 5mm Hg diastolic pressure and the left 
ventricular developed pressure (LVDP) and heart rate (HR) were recorded by the Lab Chart 
software (AD heart perfusion instruments). Every heart underwent a normal perfusion at a flow 
rate of 4 ml/min for 30 min followed with 15 min no-flow global ischemia.  The hearts were then 
reperfused with K-H buffer at a recovered flow rate (4 ml/min).  
At the end of the reperfusion, hearts were collected and either put in MESH buffer for 
mitochondrial isolation and AUR assays or subjected to triphenyltetrazolium chloride (TTC) 
staining for estimation of infarct size. ROS release assays were performed as described in 
sections 2.4.1 and 2.4.2. The TTC staining is used to measure the infarct size. The TTC staining 
buffer was firstly prepared. The detailed recipe is as given below in table 2.5. The heart was 
taken and 5ml of the TTC stain was injected into the heart at 37° C. Then the heart was stored in 
formalin. For the infarct size determinations, the sections of the heart were taken and were 
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visualized under a microscope. Image-J software was used to determine the area of the infarct 
size 
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Figure 2.4-The Langendorff heart perfusion system. 
This system was used to perform ex vivo heart perfusion and conduct cardiac global ischemia-
reperfusion.  Cardiac function was evaluated by heart rate and left ventricular developed 
pressure. 
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Table 2.5-Detailed recipe of the TTC stain 
 
 Ingredients Quantity 
Buffer 1 NaPO4 Dibasic 12.4 g/l 
 Dextran 76.5 g/l 
Buffer 2 NaPO4 Monobasic 12.4 g/l 
 Dextran 76.5 g/l 
Buffer 3 Buffer 1 800 ml 
 Buffer 2 200 ml 
Working buffer Buffer 3 100 ml 
 TTC 1g 
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2.5.1 Measurement of mitochondrial NAD(P)H levels following IR injury 
 
Mitochondrial NAD(P)H levels following IR injury was tracked by measuring the 
autofluorescence of the nicotinamide group. Following IR injury, hearts were quickly placed in 
ice-cold MESH buffer and the mitochondria were isolated as described above. Mitochondria 
were then diluted to 1 mg/mL in MESH and 20 µL aliquots were added to wells of a 96-welled 
black plate containing 180 µL of MESH. NAD(P)H autofluorescence was tracked using a 
SpectraMax M5 plate reader operating at 376 nm/420 nm excitation and emission wavelengths. 
A standard curve generated by different concentrations of NAD(P)H (1mM in 1ml MESH stock 
solution, Sigma-Aldrich) was used for calculating the amount of NAD(P)H as discussed above in 
Figure 2.5 
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Figure 2.5 NAD(P)H standard curve for measuring NAD(P)H levels after IR injury 
The fluorescence was measured by increasing the amount of NAD(P)H. Hence, the unknown 
concentration of NAD(P)H was determined. 
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2.6 Data Analysis 
All experiments were performed in duplicate and the average of duplicates taken. Data was 
analyzed in Microsoft Excel 2013. Absolute rate data was expressed as a percent change to 
control. GraphPad Prism 6 software was used to perform statistical analyses. Two-tailed paired 
Student T-Test and one-way or two-way analysis of variance (ANOVA) with Tukey’s post-hoc 
test were used for statistical analysis. All values are shown as mean +/- SEM (standard error 
mean). (* or 
#
< 0.05, ** or 
##
 < 0.01, *** or 
###
P < 0.001, **** or 
####
P < 0.0001). 
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3. Results 
3.1 Mouse genotyping and immunoblotting for NDUFS4 
Successful knockout of the NDUFS4 was achieved by the removal of exon 2 in the gene 
encoding this protein. Mice heterozygous (NDUFS4+/-) or homozygous (NDUFS4-/-) and WT 
littermates were identified by amplifying the Ndufs4 gene by PCR and agarose gel 
electrophoresis (Figure 3.1). Ear notch samples from NDUFS4+/- mice contained two PCR 
products at ~200 and 400 bp, respectively. By contrast, the WT PCR product had a mass of ~200 
bp and the NDUFS4-/- samples contained a ~400 bp fragment. To confirm successful knockout 
the absence or presence of the NDUFS4 protein by immunoblot was examined. Figure 3.2 
demonstrates that mice that were identified as homozygous for the Ndufs4 gene did not contain 
any detectable protein whereas heterozygotes displayed a ~50% decrease relative to the WT 
samples.  
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Figure 3.1- Identification of mice heterozygous or homozygous for the Ndufs4 gene by PCR 
and agarose gel electrophoresis 
 
Genetic material was extracted from ear notches and subjected to PCR amplification and then the 
relative size of the product was assessed by agarose gel electrophoresis. A band at 200 bp or 400 
bp band corresponded to samples collected from WT or NDUFS4
-/-
 mice. NDUFS4+/- samples 
contained both 200 bp and 400 bp. 
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Figure 3.2- Confirmation of partial or full ablation of NDUFS4 protein expression 
A) Western blot analysis of NDUFS4 protein levels in liver mitochondria. Succinate 
dehydrogenase subunit A (SDHA) was used as the loading control B) Densitometric 
analysis of NDUFS4 normalized to SDHA. N=2.  
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3.2 Impact of NDUFS4 deficiency on organ and body weight 
Mice homozygous for the Ndufs4 gene rapidly develop severe encephalomyopathy and 
heart disease by 5-6 weeks of age, which is associated with deficiencies in linear growth 
(105,106). Thus, before proceeding, we wanted to ensure that the partial deletion of the Ndufs4 
gene did not alter linear growth. Changes in body weight were monitored once a week from 4 to 
8 weeks of age. WT and NDUFS4+/- mice displayed no difference in overall body weight over 
the 5-week period, an observation that is consistent with previous publications (105,107) (Figure 
3.3). We also weighed heart and liver tissue to ascertain if NDUFS4+/- mice displayed any 
abnormal changes in these organs. It was observed that the partial deletion of the Ndufs4 gene 
induced no changes in cardiac (Figure 3.4) or liver weight (Figure 3.5).  
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Figure 3.3-Body weight profile for WT and NDUFS4 
+/-
 mice 
Overall body weight of mice in grams measured weekly from 4-8 weeks. Data are mean ± SEM, 
N= 5–6, Two-way ANOVA with a Tukey’s post-hoc test. 
 
 
 
N D U F S 4 + / - 
W T 
W
 e
 i
 g
 h
 t
 (
 g
 )
 
71 
 
 
 
 
 
 
 
 
 
Figure 3.4- Heart weight profile for WT and NDUFS4 
+/- 
mice  
Cardiac weight in grams was measured. Data are mean ± SEM, N =5-6, paired two-tailed 
Student T-Test. 
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Figure 3.5-Liver weight profile for WT and NDUFS4
+/-
mice 
Mass of the liver (g) was measured. Data are mean ± SEM, N=5–6, paired two-tailed Student T-
Test. 
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3.3. Examination of the O2
●-
/H2O2 release potential of NDUFS4 deficient mitochondria  
It has been proposed by Chouchani et al. that Complex I is the only source of O2
●-
/H2O2 
following IR injury (102). Therefore, we postulated that if this were true then a ~50% decrease in 
Complex I levels would lower ROS release from mitochondria. First, we examined if liver 
mitochondria from NDUFS4
+/-
 mice displayed any changes in ROS release. Mitochondria were 
supplemented with pyruvate, 2-oxoglutarate, or succinate in the absence of ADP to induce state 4 
respiratory conditions. We chose these respiratory conditions since state 4 respiration 
hyperpolarizes the mitochondrial inner membrane allowing for a more robust measure of the 
velocity of ROS production. In addition, state 4 conditions favor reverse electron flow to 
Complex I in the respiratory chain, allowing us to ascertain if partial loss of NDUFS4 affects the 
rate of ROS production. Liver mitochondria from NDUFS4+/- mice oxidizing pyruvate (50 μM) 
and malate (50 μM) displayed no change in O2
●-
/H2O2 production when compared to samples 
from WT littermates (Figure 3.6). To confirm this observation, we conducted a similar 
experiment using 2-oxoglutarate, another Krebs cycle substrate. No change in the rate of O2
●-
/H2O2 production was observed in NDUFS4
+/-
 mitochondria (Figure 3.6). Next, we tried 
succinate, which by-passes the Krebs cycle feeding electrons directly into the respiratory chain at 
the level of Complex II. In addition, succinate was reported to be a potent inducer of 
mitochondrial ROS release (109). Liver mitochondria oxidizing succinate (50 μM) displayed no 
change in the rate of ROS production (Figure 3.6). Similar studies were carried out using cardiac 
mitochondria from WT and NDUFS4
+/-
 mice. Mitochondria were supplemented with 
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Figure 3.6-Partial loss of the Ndufs4 gene does not alter O2
●-
/H2O2 release from liver 
mitochondria 
 
The rate of O2
●-
/H2O2 production by liver mitochondria supplemented with A) 50 μM pyruvate 
and 50 μM malate, B) 50 μM 2-oxoglutarate and 50 μM malate, or C) 50 μM succinate was 
estimated using the AUR assay. Changes in fluorescence were measured at 565/600 nm. Data are 
mean ± SEM, N = 5, paired two-tailed Student T-Test.  
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Figure 3.7- Partial loss of the Ndufs4 gene does not alter O2
●-
/H2O2 release from cardiac 
mitochondria 
 
The rate of O2
●-
/H2O2 production by cardiac mitochondria supplemented with A) 50 μM 
pyruvate and 50 μM malate, B) 50 μM 2-oxoglutarate and 50 μM malate, or C) 50 μM succinate 
was estimated using the AUR assay. Changes in fluorescence were measured at 565/600 nm. 
Data are mean ± SEM, N = 5, paired two-tailed Student T-Test . 
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pyruvate, 2-oxoglutarate, or succinate as described above and then rates for ROS release were 
recorded. No changes were observed in the rate of O2
●-
/H2O2 production (Figure 3.7). 
Collectively, these findings indicate that partial loss of NDUFS4 does not alter O2
●-
/H2O2 
production under state 4 respiratory conditions.  
3.4 Identification of the high capacity sites for O2
●-
/H2O2 production in liver and heart 
mitochondria 
As indicated above, Chouchani et al indicated that Complex I was the sole ROS source in 
cardiac tissue subjected to IR injury (102). However, our group and others have demonstrated 
that mitochondria in liver, heart and muscle can contain up to 12 sites for ROS production 
(103,110,111). In addition, our group has found that Complex I makes a negligible contribution 
to overall ROS production in liver mitochondria and Complex III is the major producer in 
cardiac mitochondria (110,111). Therefore, whether or not Complex I was 1) a major ROS 
generator and 2) the only ROS source of production, was tested in liver and cardiac 
mitochondria. To do so, different site-specific ROS release inhibitors were used (Figure 2.3).  
First, which sites served as major ROS producers in liver mitochondria was examined 
with pyruvate or 2-oxoglutarate (Figure 3.8). Malate was also included in the reaction mixtures 
to prime the Krebs cycle. We chose to examine ROS release from liver mitochondria from WT 
or NDUFS4
+/-
 first since we had previously established that OGDH, PDH, and Complex III were 
the chief producers in liver mitochondria from C57Bl6N mice (110). All the inhibitors 
significantly decreased ROS production by liver mitochondria supplemented with either pyruvate 
or 2-oxoglutarate in comparison to the control (no inhibitor added). KMV and CPI-613 
decreased ROS production by ≥90% in liver mitochondria collected from WT and NDUFS4 
mice. It is important to note that both inhibitors can also impede mitochondrial NADH 
77 
 
production, an important factor for ROS release from the respiratory chain. Therefore, inhibitors 
for Complex II and III were utilized to ascertain how much ROS was released from either site. 
Myxothiazol lowered ROS production by ~50% in WT and NDUFS4
+/-
 liver mitochondria 
(Figure 3.8). In addition, atpenin A5 decreased production by ~80% relative to control (no 
inhibitors) (Figure 3.8). It is worthy to note as well that we observed no statistical differences in 
the rates of ROS release between WT and NDUFS4+
/-
 liver mitochondria treated with or without 
the different inhibitors except in mitochondria treated with myxothiazol. In that particular case, a 
small but significant increase in ROS release was observed in the NDUFS4
+/-
 mitochondria when 
compared to WT samples treated with myxothiazol (Figure 3.8).  Based on these findings, 
Complexes II and III serve as the major sources of ROS release in liver mitochondria when 
Krebs cycle-linked metabolites serve as substrates. It is also likely that PDH and OGDH make 
minor contributions as well and Complex I makes a negligible contribution. 
 Next, the high velocity sites for ROS release were examined in heart mitochondria. 
Experiments were initially designed as described above, utilizing pyruvate or 2-oxoglutarate and 
malate as substrates (Figure 3.9). It was found that KMV and CPI-613 augmented ROS release, 
but only when pyruvate served as the substrate (Figure 3.9). Inclusion of KMV or CPI-613 did 
not change ROS production when 2-oxoglutarate served as the substrate. This could be attributed 
to the inhibition of NADH production which would limit the production of ROS by the electron 
transport chain. when pyruvate was the substrate (Figure 3.9).  
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Figure 3.8- Assessment of which enzymes serve as high velocity ROS producers in liver 
mitochondria 
 
Liver mitochondria were supplemented with (A) 50 μM pyruvate or (B) 50 μM 2-oxoglutarate 
and treated with or without 10 mM KMV, 250 µM CPI-613, 4 µM myxothiazol, or 40 µM 
atpenin A5 and then ROS release rates were tracked with AUR reagent. All samples were also 
supplemented with 50 μM malate. Changes in fluorescence were measured at 565/600 nm. 
Results were normalized to control ROS release rates to estimate the individual contributes of the 
different sites towards overall production. Data are mean ± SEM, N = 5, Two-way ANOVA with 
Tukey’s post hoc test, *P < 0.05, ####P <0.001. * corresponds to statistical comparisons between 
genotypes for mitochondria treated with or without inhibitors and # corresponds to statistical 
comparisons of inhibitor effect relative to control. 
 
 
 
 
 
 
   
A.  B.  
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Figure 3.9-The electron transport is the major source for ROS release in cardiac 
mitochondria 
 
Cardiac mitochondria were supplemented with (A) 50 μM pyruvate or (B) 50 μM 2-oxoglutarate 
and treated with or without 10 mM KMV or 250 µM CPI-613 and then ROS release rates were 
tracked with AUR reagent. All samples were also supplemented with 50 μM malate. Changes in 
fluorescence were measured at 565/600 nm. Results were normalized to control ROS release 
rates to estimate the individual contributes of the different sites towards overall production. Data 
are mean ± SEM, N = 5, Two-way ANOVA with Tukey’s post hoc test, **P<0.01, ## P<0.01. * 
corresponds to statistical comparisons between genotypes for mitochondria treated with or 
without inhibitors and # corresponds to statistical comparisons of inhibitor effect relative to 
control. 
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Few differences in the ROS release profile were observed between WT and NDUFS4
+/-
 cardiac 
mitochondria (Figure 3.9). However, it was noted that NDUFS4
+/-
 mitochondria treated with 
KMV displayed a higher rate of ROS release when compared to WT mitochondria 
3.5 O2
●-
/H2O2 production by cardiac tissue supplemented with succinate  
The results collected in Figure 3.9 indicate that the electron transport chain may be the chief site 
for ROS release in cardiac mitochondria. Succinate does induce high rates of ROS release in 
cardiac mitochondria and our group has found that Complex I and III are the main generators in 
heart tissue (111). In addition, other groups have found that succinate does accumulate in cardiac 
tissue following reperfusion injury, driving high rates of ROS release from the respiratory chain 
(111). Therefore, mitochondria oxidizing only succinate was used to identify which complex in 
the electron transport chain produced the most ROS. No genotype effect was observed indicating 
WT and NDUFS4
+/-
 display similar rates of ROS release in the absence or presence of the 
different inhibitors and when succinate served as the sole source of electrons (Figure 3.10). 
However, it was found that Complex III was the major source of ROS in cardiac mitochondria 
oxidizing succinate under state 4 respiratory conditions. Indeed, myxothiazol induced a ~50% 
decrease in ROS release relative to control in WT and NDUFS4
+/-
 cardiac mitochondria (Figure 
3.10). It was also observed that rotenone, which inhibits reverse electron flow to Complex I, 
thereby curtailing ROS release, also decreased O2
●-
/H2O2 production by ~30%. Finally, atpenin 
A5, which also blocks flow from Complex II to the rest of the chain, decreased ROS production 
by almost 80% (Figure 3.10). Therefore, the hierarchy for ROS release from highest to lowest in 
cardiac mitochondria is Complex III (~50% production) > Complex I (~30% production) > 
Complex II (~20% production) when succinate is the substrate. 
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Figure 3.10- Complex III is the major ROS source in cardiac mitochondria   
Cardiac mitochondria were supplemented with 50 μM succinate and treated with 4 µM rotenone, 
4 µM myxothiazol, or 40 µM atpenin A5 and then ROS release rates were tracked using the AUR 
assay. Changes in fluorescence were measured at 565/600 nm. Results were normalized to 
control ROS release rates to estimate the individual contributes of the different sites towards 
overall production. Data are mean ± SEM, N = 5, Two-way ANOVA with Tukey’s post hoc test, 
####P <0.001. * corresponds to statistical comparisons between genotypes for mitochondria 
treated with or without inhibitors and # corresponds to statistical comparisons of inhibitor effect 
relative to control. 
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3.6 Assessment of the induction of electrophilic cell signaling pathways 
It is possible that increased expression of H2O2 clearing enzymes could account for the 
lack of difference in ROS release between cardiac mitochondria isolated from WT and 
NDUFS4
+/-
 mice. Therefore, we conducted immunoblot analyses to determine if mitochondrial 
H2O2 clearing enzymes, GPX1 and TRX2, displayed any changes in protein levels. It was found 
that partial deletion of the Ndufs4 gene increased the protein levels of both GPX1 and TRX2, 
two crucial enzymes involved in eliminating ROS (Figure 3.11). Collectively, these results 
demonstrate that the lack of difference in ROS release between WT and NDUFS4
+/-
 mice was 
related to an increase in antioxidant defenses. 
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Figure 3.11- Partial deletion of the Ndufs4 gene increases GPX1 and TRX2 levels 
NDUFS4 deficiency increased the induction of electrophilic stress signaling pathways. A) 
Western blot with 10 µg protein using anti-GPX1 and anti-TRX2 wherein SDHA was used as a 
loading control.  B) Densitometry analysis of GPX1/SDHA. C) Densitometry analysis of 
TRX2/SDHA. Data are mean ± SEM, n=2. 
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3.7 Examination of the effect of IR injury on NDUFS4-deficient mice  
3.7.1 Impact of NDUFS4 deficiency on contractile recovery from reperfusion injury  
The results collected above indicate that there is no difference in the ROS release profile 
in cardiac mitochondria collected from mice with a partial deficiency in the Ndufs4 gene, which 
could be related to an increase in electrophilic stress signaling and the increased expression of 
antioxidant defense enzymes. It was also observed that Complex III is the major ROS source, not 
Complex I. Next, the response of NDUFS4
+/-
 mice towards reperfusion injury was assessed.  
During the normal perfusion period, the WT and NDUFS4
+/-
 mice displayed a similar cardiac 
output (LVDP*HR index) (Figure 3.12). However, after 15 minutes of ischemia, the functional 
recovery of the WT hearts are much better than NDUFS4 
+/- 
hearts (Figure 3.12). Following a 30 
minute full  reperfusion, both WT and NDUFS4 
+/-
 hearts were subsequently sectioned and 
subjected to TTC staining to evaluate cardiac post-ischemic injury (infarct size). It was found 
that infarct size comprised ~60% of the total myocardial area in NDUFS4
+/-
 hearts whereas it 
made up ~39% of the area in WT samples (Figure 3.13). Taken together, partial loss of Complex 
I sensitizes the myocardium to ischemia-reperfusion injury leading to cardiac dysfunction. 
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Figure 3.12-Comparison of the contractile status between the genotypes 
The cardiac output of the NDUFS4
+/-
 and the WT mice was compared using a Langendorff 
assembly at several stages. Data are mean ± SEM, N=5, paired two-tailed Student T-Test. 
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Figure 3.13-Comparison of the infarct size in WT and NDUFS4
+/-
 hearts following an IR 
challenge.
 
 
Myocardial necrosis determined by (A) TTC staining and (B) quantification of the affected area. 
Data are mean ± SEM, N = 9, paired two-tailed Student T-Test, *P < 0.05. 
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3.7.2. Partial loss of Complex I augments ROS release from NDUFS4
+/-
 mitochondria following 
reperfusion injury. 
  Our finding that NDUFS4
+/- 
cardiac mitochondria contain higher amounts of H2O2 
eliminating enzymes led to the genesis of the hypothesis that the increased sensitivity of the 
myocardium towards IR injury in Complex I deficient mice is related to increased mitochondrial 
ROS production. Therefore, we tested the ROS forming potential of cardiac mitochondria 
isolated from WT and NDUFS4
+/-
 mice subjected to IR injury. It was found that NDUFS4
+/-
 
mitochondria produced significantly more ROS than WT samples regardless of substrate (Figure 
3.14). Indeed, oxidation of pyruvate, 2-oxoglutarate, or succinate induced between a ~50-100% 
increase in ROS production by NDUFS4
+/- 
mitochondria following IR injury (Figure 3.14). We 
wanted to determine if these affects were related to changes in the redox potential of the 
mitochondrial nicotinamide pools. No changes in mitochondrial NAD(P)H levels were observed 
indicating the changes in ROS release were not associated with the capacity to generate NADH 
or NAD(P)H (Figure 3.15). 
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Figure 3.14-Assessment of the % O2
●-
/H2O2 production between the genotypes in IR 
challenged cardiac tissues 
 
Comparing the % ROS production between the NDUFS4
+/-
 and the NDUFS4
+/+
 mice 
supplemented with 50 µM malate with either 50 µM (A) pyruvate or (B) 2-oxoglutarate or (C) 
succinate. AUR fluorescence was measured at 565/600 nm. Data are mean ± SEM, N = 5, paired 
two-tailed Student T-test, *P <0.05. 
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Figure 3.15-Comparison of the NADH driven ROS production between the genotypes 
 
AUR fluorescence was measured at 376-420 nm. Data are mean ± SEM, N =4- 5, paired two-
tailed Student T-Test. 
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3.8 Utilization of Complex I knockout mitochondria to assess NADH-driven ROS release 
by OGDH and PDH 
It has been known for some time that Complex I can generate high amounts of ROS by 
reverse electron flow from Complex II when the mitochondrial inner membrane is highly 
polarized (e.g. under state 4 respiratory conditions). It has also been documented that OGDH and 
PDH can also produce ROS by reverse electron flow from NADH (110,112). In this scenario, 
accumulation of NADH due to defective Complex I activity results in its re-oxidation by OGDH 
and PDH, inducing ROS release from the E3 subunit of either enzyme complex. However, all 
studies demonstrating that OGDH and PDH can form ROS by reverse electron flow have been 
conducted with purified enzymes (112). Therefore, the physiological relevance of ROS 
production from either enzyme by reverse flow has always been questioned. Since we possessed 
a Complex I deficient mouse model, we decided to test if ROS could be produced by liver and 
cardiac mitochondria treated with different concentrations of NADH. For these assays, we 
isolated mitochondria from 5-week old mice homozygous for Ndufs4 to ensure that there would 
be no Complex I to turn over NADH. Mitochondria were permeabilized to allow NADH uptake 
which also depolarized mitochondria inhibiting transhydrogenase activity and preventing reverse 
electron flow in the ETC. As demonstrated in Figure 3.16, a robust increase in ROS release was 
observed with increasing NADH levels. As per the results obtained by our experiments we could 
see a concentration dependent increase in the O2
●-
/H2O2 production in the liver tissue with the 
increasing concentration of NADH (Figure 3.16). A significant increase in the % O2
●-
/H2O2 
production was seen when 5µM and 10µM NADH was used in the liver tissue. Similarly, the 
cardiac tissue was also supplemented with various concentrations of NADH. The results 
obtained in the cardiac tissues were similar to that obtained in the liver tissues. A concentration 
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dependent increase was seen in the % O2
●-
/H2O2 production with the increasing NADH 
concentrations. A significant increase in the % O2
●-
/H2O2 production was seen when 5 µM 
NADH was used (Figure 3.16). Thus, these results prove NADH to be responsible for the 
increase in ROS production. These preliminary results show that NADH can induce ROS release 
potentially by OGDH and PDH by RET.  
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Figure 3.16-Assessment of % O2
●-
/H2O2 production in mitochondria supplemented with 
NADH 
 
A) 0.3 mg/ml liver mitochondria was supplemented with 0 µM - 10 µM NADH or (B) 0.1 mg/ml 
cardiac mitochondria was supplemented with 0 µM - 5 µm NADH. AUR fluorescence was 
measured at 565/600 nm. N = 4, One-way ANOVA with a Tukey’s post-hoc test,*P< 0.05 and 
**P< 0.01. 
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4. Discussion 
4.1 Summary 
ROS are oxygen-containing free radicals formed due to the premature leaking of the 
electrons from the flavin-containing dehydrogenases or electron carriers in the ETC to oxygen. 
ROS have a dual nature; at higher concentrations, they can be harmful but can serve as signaling 
molecules at low levels (114). ROS can be produced by various sites in the electron transport 
chain or by flavin-containing enzymes that combust carbon. For the past decade, Dr. Martin 
Brand’s group has been characterizing the velocity of ROS release from these individual sites in 
permeabilized muscle mitochondria (103). OGDH and PDH were found to produce 8x and 4x 
more ROS, respectively, when compared to Complex I and Complexes II and III served as high 
capacity sites for release as well (103). Complex I can be a critical source but only during reverse 
electron flow from the UQ pool. Chouchani et al proposed that Complex I is the sole ROS source 
in mitochondria from hearts subjected to IR injury. This is unlikely considering it is well known 
that mitochondria can contain a number of ROS sources. Therefore, the goal of this thesis was to 
ascertain if Complex I was the sole ROS source in hearts subjected to IR injury. This was tested 
using a mouse model that had a 50% decrease in Complex I availability due to partial removal of 
the Ndufs4 gene. The findings from my thesis indicate that Complex II and III are major sources 
in liver mitochondria with OGDH and PDH making minor contributions (109). In cardiac 
mitochondria on the other hand, it was demonstrated that the hierarchy of production, from 
highest to lowest capacity site, was Complex III > Complex I > Complex II with OGDH and 
PDH making negligible contributions (109). Thus, Complex I was not the sole producer of ROS 
in heart mitochondria (109). Moreover, it was found that mice heterozygous for the Ndufs4 gene 
displayed increased sensitivity towards reperfusion injury. These results not only contradict the 
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findings by Chouchani et al., but also show that fully active Complex I may be vital for 
protecting the heart from ischemic damage. Indeed, loss of Complex I sensitized hearts towards 
reperfusion injury which was associated with diminished heart performance recovery. These 
results correlated strongly with an increase in mitochondrial ROS release indicating that 
Complex I may play a critical role in preserving electron transfer efficiency in the respiratory 
chain (109). It is important to point out that there were no differences in ROS release from WT 
or NDUFS4
+/-
 mitochondria isolated from hearts and liver tissue not subjected to IR challenge. 
However, this may be associated with an increase in the protein levels of the ROS clearing 
enzymes, GPX1 and TRX2 (109).  
4.2 Complex I is not the sole ROS source during myocardial reperfusion injury 
Complex I is often considered the most important ROS source in cells, including cardiac 
tissue (102). In addition, it was recently reported that Complex I is the sole ROS source in 
cardiac tissue, accounting for 100% of the damage associated with reperfusion injury (102). 
Ischemia followed by reperfusion can cause considerable damage to the myocardium and is still 
considered the number one contributor to heart disease (102). Ischemia cuts off the supply of 
oxygen and nutrient rich blood to the myocardium. As noted in the introduction, this can have a 
number of effects including acidification of the myocardium and the accumulation of purine 
nucleotides. In mitochondria, ischemia results in the over-reduction of the respiratory chain and 
the accumulation of several metabolites, including NADH and succinate. NADH accumulates 
due to the absence of O2 and electron flow in the respiratory chain and subsequent return of 
protons to the matrix by Complex V (or other solute transporters). According to Chouchani et al, 
the accumulation of succinate occurs due to the reduction of fumarate by the reversal of 
Complex II (102). Fumarate is generated by the purine nucleotide chain (PNC) or malate 
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aspartate shunt (MAS) which is then taken up by mitochondria and converted to succinate 
through reverse electron flow from the UQ pool to the active site of Complex II (102). 
Subsequent reperfusion of the myocardial tissue restores oxygen and nutrient levels 
which is vital for the recovery of viable tissue. However, it paradoxically induces heart damage 
and can account for ≥50% of the injury associated with ischemia-reperfusion (122). Although a 
clear picture for the mechanism of reperfusion injury has started to develop, the role of 
mitochondria in this process still remains poorly understood. According to Chouchani et al, 
succinate accumulation during ischemia is responsible for reperfusion injury and ignition of ROS 
production under these conditions is mediated solely by reverse electron flow to Complex I 
(102). However, as noted in Section 1.4.2 in the Introduction, problems with this model arise 
when one starts to carefully consider the bioenergetics required to drive RET from succinate to 
Complex I to induce this massive burst in ROS production. Another important consideration is 
the fact that mitochondria can contain up to 12 sites for production and that the results from 
Chouchani et al completely ignore studies demonstrating that Complex II and III also serve as 
high capacity sites for production following IR injury (124,103,115). 
In the present study, three critical observations were made that refute the claim that 
Complex I is the sole source of ROS during IR injury. The first stems from inhibitor studies that 
showed that Complex III was the highest capacity site for ROS release from cardiac 
mitochondria isolated from WT and NDUFS4
+/-
 mice. Using myxothiazol, which inhibits the 
production of semiquinone radicals in the QO site in the complex, it was demonstrated that 
Complex III accounted for ~50% of the ROS produced when succinate was the substrate. 
Complex I produced ~30% of the ROS when succinate was being oxidized and Complex II 
generated the rest (~20%). OGDH and PDH made negligible contributions to mitochondrial ROS 
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production. These observations fall in line with a previous study published by our group that 
showed that Complexes III and I were the major ROS sources in cardiac mitochondria isolated 
from C57Bl6N mice (111). What is also note-worthy about this observation as well is that these 
results were collected with mitochondria respiring under state 4 conditions (absence of ADP), 
which would favor the hyperpolarizing of the electrochemical potential of protons across the 
inner membrane. Therefore, even under conditions that favor RET from succinate to Complex I, 
Complex III is still the highest capacity site. The second major observation demonstrating that 
Complex I is not the sole source is the finding that partial ablation of the Ndufs4 gene actually 
augmented ROS production from mitochondria isolated from hearts subjected to reperfusion 
injury. If Complex I is the sole source, then even its partial loss should at the very least have 
some protective effect against IR injury. However, this was not the case in this study. The final 
observation is associated with results collected in Figure 3.7 where it was found that the loss of 
NDUFS4 did not alter ROS release from mitochondria respiring under state 4 conditions. Again, 
if Complex I was the sole supplier of ROS in heart tissue then its partial loss should have 
diminished the rate of production. Moreover, we did not see any change in the rate of ROS 
production in the WT and the NDUFS4
-/-
 mice which shows that the NDUFS4 deficiency did not 
alter the O2
.-
/H2O2 production. Also, as per the previous research in our lab, Complex I was 
found to be a negligible source of ROS in the liver and Complex III was shown to be a major 
source of ROS in the cardiac tissue (110,111). In fact, we found that heart mitochondria actually 
contained higher amounts of GPX1 and TRX2, two key factors involved in the clearance of 
H2O2. Therefore, it may be that mitochondria in the myocardium of NDUFS4
+/-
 mice may 
initially produce more ROS which is then offset over its lifespan by the induction of electrophilic 
stress signaling pathways and the stabilization of NRF2, a transcription factor that induces the 
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expression of genes encoding antioxidant enzymes. However, no studies have shown that loss of 
complex I alters NRF2 expression.   
One critical factor that was not measured in this study was MPTP opening following 
reperfusion and the timing of its opening relative to the ignition of ROS production. Chouchani 
et al found that the initial burst in ROS production occurred within a few seconds and was found 
to be responsible for MPTP opening and the induction of cell death and tissue damage (102). By 
contrast, several studies published by Dr. Andrew Halestrap’s group over the past two decades 
consistently showed that MPTP opening occurs within seconds due to calcium overloading 
(115,149,150,151,152). The burst in ROS release and subsequent myocardial damage occurs 30 
seconds to 1 minute after opening (115). Intriguingly, cyclosporin A can prevent the immediate 
opening of the MPTP after reperfusion (136,138). Likewise, ROS production blockers and 
mitochondria-targeted antioxidants or ischemic precondition, which bolsters endogenous 
antioxidant defenses, have been found to protect from damage (137). Taken together, although 
we did not measure the timing for ROS release and MPTP opening following reperfusion, it is 
clear that both ROS from mitochondria and MPTP are involved in myocardial damage.  
4.3 Can Complex I protect from ischemia-reperfusion injury? 
 In the present study, it was found that the partial deletion of the Ndufs4 gene sensitizes 
the myocardium towards reperfusion injury. This was associated with poor contractile recovery 
following a bout of stop-flow ischemia, which correlated strongly with a significant increase in 
ROS production (109). These results are in line with another study that found that the complete 
ablation of Ndufs4 accelerates the induction of heart disease in mice (125). In addition, selective 
loss of Complex I due to NDUFS4 deficiency was also found to induce severe hypertrophic 
cardiomyopathy (102). Collectively, this would suggest that fully functional Complex I can 
98 
 
protect the myocardium from heart disease. Indeed, loss of Complex I function is associated with 
the development of a number of disorders, including Leigh’s syndrome, which is associated with 
defects in the expression of NDUFS4 (105). In fact, Leigh’s syndrome is characterized by the 
over production of mitochondrial ROS and oxidative distress (105). In this thesis, it was found 
that even a ~50% decrease in Complex I can significantly increase the sensitivity of the 
myocardium towards heart damage. Although speculative, this could be due to the re-distribution 
of electrons in the respiratory chain, prompting increased ROS release from more potent sites of 
production like Complex III. Indeed, it has been found that inhibitors for ROS production by 
Complex III, like myxothiazol and stigmatellin, can be protective against reperfusion injury 
(124).  
 Temporary inhibition of Complex I followed by the full recovery of its activity has been 
found to protect heart tissue and other organs from reperfusion injury. Indeed, Complex I adopts 
a fully deactivated “D” confirmation for up to 12 minutes after reperfusion (132). Complex I 
deactivation can be prolonged by the modification of Cys39 in ND3 subunit of the complex. The 
ND3 subunit forms a critical part of the UQ binding pocket. S-nitrosylation of the ND3 subunit 
in the D state can prolong Complex I deactivation which can protect from damage (123). In 
addition, similar results have been collected with iodoacetamide and N-ethylmaleimide (133). It 
has even been postulated that ND3 can be S-glutathionylated to afford prolonged protection from 
IR injury (130). However, it should be noted that this deactivation needs to be temporary since 
chronic Complex I inhibition can exacerbate heart damage. 
4.4 Impact of the deletion of the Ndufs4 gene on mouse and cell physiology 
 The observation that the partial deletion of the Ndufs4 gene sensitizes the myocardium to 
reperfusion-induced heart disease is in line with studies that found that the total ablation of 
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NDUFS4 accelerates heart failure and induces fatal encephalomyopathy, blindness, and lethargy 
(125,105). In fact, we made similar observations where mice completely lacking NDUFS4 
develop alopecia, blindness, and display stunted growth and lethargy. However, linear growth 
rate and organ weights of mice heterozygous for the Ndufs4 gene were similar to the WT 
littermates demonstrating that its partial loss does not affect overall mouse physiology, an 
observation that is consistent with previously published studies (109,105). Variances in the gene 
encoding Ndufs4 has also been linked to the development of Leigh’s syndrome in humans and 
has been speculated to contribute to the development of heart disease (127). Therefore, 
understanding the molecular and biochemical consequences of the partial loss of Ndufs4 is 
crucial for delineating how defects in Complex I assembly contribute to the pathogenesis of heart 
diseases and neurological disorders. Karamanlidis et al observed that the complete ablation of 
the Ndufs4 gene actually diminished mitochondrial H2O2 production, but only when 
mitochondria were metabolizing succinate (125). However, the decrease in ROS release was 
very small. By contrast, when pyruvate and malate served as the substrates, no difference in ROS 
release was recorded (125). Furthermore, no changes in H2O2 release from heart mitochondria 
were observed when antimycin A or ADP were added to reaction mixtures, experimental 
conditions that promote and prevent ROS production, respectively (125). Finally, there is only a 
very small, but significant, decrease in ROS produced by mitochondria in isolated 
cardiomyocytes. The findings in this thesis confirm some of the results reported by Karamanlidis 
et al since no difference in ROS release was observed in our system unless hearts were subjected 
to reperfusion injury (125). It should be noted, however, that we did not observe any decrease in 
ROS release when succinate was being oxidized. This contrasts with results reported by 
Karamanlidis et al where it was found that total ablation of Ndufs4 leads to ~25% decrease in 
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ROS release (125). This discrepancy can be explained by the fact that ROS release assays in this 
study were conducted on mice heterozygous for NDUFS4 (109). Therefore, it is likely that we 
observed no differences in ROS release when succinate was the substrate simply because 
Complex I was still present, even though its expression was diminished by ~50%, in our system 
(109).  
 In another study, Valsecchi et al found that the elimination of the Ndusf4 also does not 
alter ROS release in cultured mouse embryonic fibroblasts (MEF) (120). However, removal of 
the Ndufs4 gene did decrease O2 consumption in intact MEF cells, even though ROS production 
was unaltered (120). It should be emphasized dihydroethidine was utilized to measure ROS 
releases in this study (120). This is problematic for several reasons. First, dihydroethidine, 
although specific for O2
●-
, only reacts with it at a rate of 2 x 10
7
 M
-1
s
-1
, which is two orders of 
magnitude lower than the activity of SOD (114). Therefore, although it is specific for O2
●-
 it is 
not that sensitive. Another issue with using dihydroethidine is the fact that it is a cytosolic probe 
and does not specifically measure ROS formed in the matrix of mitochondria (114). This is 
important since most of the ROS generating enzymes in the mitochondria make contact with the 
matrix. Finally, dihydroethidine does not measure H2O2, the main ROS generated by 
mitochondria and found throughout the cell (114). However, despite these shortcomings, the 
results generated with cultured cells by Valsecchi et al confirm, to a certain degree, the findings 
generated in this thesis; 1) that partial loss of NDUFS4 does not alter ROS production and 2) 
ROS production by cardiac mitochondria lacking NDUFS4 can increase only when the heart is 
subjected to a reperfusion challenge (120).   
Another important observation made in this thesis was that the partial deletion of the 
Ndufs4 gene increased the protein expression levels of GPX1 and TRX2, two important H2O2 
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eliminating enzymes found in the matrix of mitochondria (109). It is therefore entirely possible 
that the absence of a difference in ROS release from WT and NDUFS4
+/-
 cardiac mitochondria 
was due to the increased availability of H2O2 removing enzymes in the hearts collected from 
heterozygous mice. This effect is likely due to the activation of stress signaling pathways such as 
the NRF2 cascade which augments the expression of genes involved in the adaptation of cells 
towards oxidative distress. Unfortunately, the impact of the loss of NDUFS4 on the NRF2 
pathway has never been investigated. However, the results collected here would suggest that 
defects in Complex I assembly can trigger a stress response that allows the adaptation of cells 
towards increased ROS levels.   
4.5 OGDH and PDH as a source of ROS in liver mitochondria 
In 2004, it was shown for the first time that OGDH can produce ROS in synaptosomes 
(128). This finding demonstrated that Complex I and III were not the sole ROS sources in 
mitochondria and that other flavin-containing enzymes could serve as generators as well. A full 
decade later, it was established that OGDH and PDH can generate ~8x and ~4x more ROS than 
Complex I in muscle mitochondria (126). Similar results were collected with permeabilized 
muscle fibers where it was found that PDH is a major source of ROS (129). A few years later, 
Slade et al showed for the first time that OGDH can account for up to ~30% of the ROS released 
by liver mitochondria (110). In the same study, Complex III made up ~50% of the total 
production and PDH only accounted for 7-12% (110). Complex I made a negligible contribution. 
These observations were confirmed in a second study published by the Mailloux group, where it 
was demonstrated that PDH and OGDH are not only significant sources of ROS, but also 
important sites for regulation by redox signals (112). Overall, these findings have provided 
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conclusive evidence that OGDH and PDH can serve as major ROS sources in muscle and liver 
tissue.  
In Figure 3.8 of this thesis, different inhibitors were employed to ascertain 1) the impact 
of partial loss of Complex I on ROS release from several major sites of production and 2) which 
ROS source produces the most ROS. KMV, a highly specific inhibitor for ROS release from 
OGDH, and CPI-613, which inhibits ROS production by PDH and OGDH and other 2-oxoacid 
dehydrogenases, almost completely abolished ROS production from liver mitochondria oxidizing 
pyruvate or 2-oxoglutarate in the presence of malate. However, to our surprise, atpenin A5 also 
induced a similar effect and myxothiazol lowered ROS release by ~50%. This would suggest that 
the major sites for production are Complex II and III and not OGDH and PDH. Atpenin A5 
blocks the UQ binding site in Complex II, which is found in the SDHD subunit and donates 
electrons from succinate to the UQ pool. In addition, the site for ROS release in Complex II is 
the FAD associated with the SDHA where succinate is oxidized to form fumarate as shown in 
Figure 1.6. In Figure 3.8, pyruvate and 2-oxoglutarate are serving as substrates meaning that 
electrons are entering at the level of Complex I through NADH oxidation. Therefore, atpenin A5 
is blocking ROS release from Complex II by preventing the reverse flow of electrons originating 
from Complex I to the FAD in the SDHA subunit. In regards to the myxothiazol effect, it is 
simply preventing semiquinone production during forward electron flow from the UQ pool. In 
addition, KMV and CPI-613 prevent ROS release from OGDH and PDH by blocking the E2 
subunit which would simultaneously inhibit NADH production (112). Taken together, Complex 
II and III are the major sites for production in liver mitochondria isolated from 129/Sv X 
C57BL/6N mice. It is now crucial to emphasize that these findings are in contrast to previous 
publications generated in our lab (110, 126). For instance, in Slade et al and O’Brien et al, it was 
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shown that OGDH and PDH are major sources in liver mitochondria collected from C57Bl6N 
mice (110,112).  It is possible that there is a strain-dependent effect on the ROS release profiles 
of liver mitochondria collected from C57Bl6N and 129/Sv X C57BL/6N mice. ROS release 
profiles differ greatly between Sprague-Dawley rat, C57Bl6N mouse, and human muscle tissue 
(129). To our knowledge, whether or not there is a true strain effect on which site(s) serve as 
major suppliers of ROS in mitochondria has never been investigated. However, based on our 
findings and previously published observations, it is likely that there is a strain-dependent effect 
in terms of which sites serve as major ROS generators in liver mitochondria. This was also 
demonstrated with 6N and 6J mice where it was found that 6J and 6N mice produced different 
amounts of ROS (153), which is similar to the observations made in our lab recently 
(unpublished results). 
 
4.6 Reverse electron transfer from NADH to OGDH and PDH 
 In 2004, it was not only observed that OGDH can produce ROS by forward electron flow 
from 2-oxoglutarate to NAD
+
 (128), but it was also found that it can also emit O2
●-
/H2O2 by 
reverse transfer from NADH (119). Using purified OGDH, Starkov et al demonstrated that 
production by reverse flow depended on the ratio of NADH to NAD
+
 (119). A higher 
NADH/NAD
+
 induced an exponential increase in ROS production. These findings led to the 
genesis of the hypothesis that defects in Complex I activity could potentially contribute to the 
development of neurological disorders through the NADH-induced production of ROS by RET 
to OGDH (119). Studies conducted by the  Mailloux lab also demonstrated that OGDH purified 
from porcine heart can display a high rate for ROS release during reverse electron flow from 
NADH (104). The rate for ROS release was dependent on the concentration of NADH and 
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OGDH was a higher capacity site for production when compared to PDH (104). Furthermore, it 
was also found in two separate studies that protein S-glutathionylation could alter ROS release 
during reverse flow from NADH to PDH and OGDH (104, 112). This would indicate that 
reverse electron flow from NADH to PDH and OGDH is an important ROS source that can be 
subjected to regulation by redox signals. 
 The drawback associated with these studies is that purified enzymes were used to 
examine OGDH and PDH ROS release due to reverse electron flow. This brings into question 
the physiological relevance of the production of ROS by OGDH and PDH during reverse 
electron flow. Indeed, it is possible that defects in Complex I could prompt the accumulation of 
NADH leading to increased ROS production by PDH and OGDH. In addition, it was found that 
as little as 1 µM NADH (which is a low physiological concentration) could induce ROS 
production by OGDH and PDH (104). Since I had access to a mouse line deficient in Complex I, 
I decided to test if NADH could stimulate mitochondrial ROS release. The logic here was that 
total ablation of Ndufs4 would prevent the turnover of NADH by Complex I promoting RET to 
OGDH and PDH in isolated mitochondria. We also decided to permeabilize mitochondria with 
Triton X-100 to promote NADH uptake but also hinder the establishment of a proton motive 
force. Indeed, the second major NADH consuming enzyme in mitochondria is transhydrogenase 
which uses the proton motive force to transfer the hydride from NADH to NADP
+
. Therefore, 
depolarizing the mitochondrial inner membrane would also inhibit transhydrogenase. Using 
permeabilized mitochondria, we were able to show for the first time that NADH can promote 
ROS release from 2-oxoacid dehydrogenases (PDH and OGDH and potentially other 2-oxoacid 
dehydrogenases). This was demonstrated in permeabilized liver and cardiac mitochondria 
isolated from NDUFS4
-/-
 mice. In addition, the rate for ROS release was dependent on the 
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concentration of NADH. Although preliminary, these findings do suggest that RET from NADH 
to 2-oxoacid dehydrogenases can produce ROS in mitochondria, pointing to the possibility that it 
may be a physiologically relevant phenomenon.   
4.7 Conclusion 
This thesis demonstrates that Complex I is not the sole source of ROS during ischemic 
reperfusion injury to cardiac tissue. According to this study, Complex III was found to be the 
major source while Complex I accounted for only ~30% of the ROS release. Complex II was 
found to be a minor source and OGDH and PDH were low capacity sites of production. In the 
liver tissue, Complex II and Complex III were found to be the major sources of ROS. The partial 
loss of Complex I did not alter ROS release from mitochondria oxidizing pyruvate, 2-
oxoglutarate, or succinate, which is attributed to the increase in GPX1 and TRX2 expression. 
Subjecting hearts from WT and Complex I deficient mice to IR injury revealed that the partial 
deletion of NDUFS4 sensitized the myocardium to damage. Mice heterozygous for NDUFS4 
displayed diminished recovery from ischemia, increased myocardial infarct size, and a 
significant increase in ROS production by isolated mitochondria following IR injury. Finally, it 
was found that production of ROS by 2-oxoacid dehydrogenases through reverse electron 
transfer from NADH may be of physiological relevance. This is based on our findings that 
demonstrated that liver and cardiac mitochondria displayed robust rates for ROS production in 
the presence of NADH and in the absence of Complex I.  
4.8 Future directions 
Based upon the results obtained in this thesis, following work could be done for the future: 
Based upon the results obtained in this thesis, following work could be done for the future: 
 
1. Testing if myxothiazol can impede IR injury in mouse hearts deficient in Complex I. The 
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observation from our present study showed Complex III to be a major source of ROS during I/R 
injury. Hence, it would be really interesting to see if myxothiazol which inhibits Complex III could 
delay IR injury.. 
2.  Fully examining the ROS forming potential of different sites of production in heart and liver. 
3. Investigating the major sources of ROS production in various strains of mice. Various strains 
of mice like C129 and C57B/6N showed differences in the sources of ROS as per an observation 
made during our experiments. Hence, comparing the sources between these mice could suggest 
us about the strain effects on the sources of ROS. 
4. Investigating if OGDH and PDH were sources of ROS production in cell lines devoid of a 
functional ETC. This was done in order to know more about RET and thus, evaluating the exact 
amount of ROS produced from OGDH and PDH. 
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